EP1227834A2 - Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders - Google Patents
Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disordersInfo
- Publication number
- EP1227834A2 EP1227834A2 EP00977538A EP00977538A EP1227834A2 EP 1227834 A2 EP1227834 A2 EP 1227834A2 EP 00977538 A EP00977538 A EP 00977538A EP 00977538 A EP00977538 A EP 00977538A EP 1227834 A2 EP1227834 A2 EP 1227834A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- caspase
- skin
- modulators
- blood
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090001132 Caspase-14 Proteins 0.000 title claims abstract description 248
- 102000004958 Caspase-14 Human genes 0.000 title claims abstract description 246
- 208000014644 Brain disease Diseases 0.000 title claims abstract description 10
- 208000017520 skin disease Diseases 0.000 title description 13
- 208000030533 eye disease Diseases 0.000 title description 3
- 230000014509 gene expression Effects 0.000 claims abstract description 89
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 55
- 230000004069 differentiation Effects 0.000 claims abstract description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 45
- 230000004888 barrier function Effects 0.000 claims abstract description 29
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 25
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 24
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 24
- 230000004913 activation Effects 0.000 claims abstract description 20
- 230000008499 blood brain barrier function Effects 0.000 claims abstract description 13
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 13
- 239000012634 fragment Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 26
- 239000002253 acid Substances 0.000 claims description 17
- 108090000994 Catalytic RNA Proteins 0.000 claims description 11
- 102000053642 Catalytic RNA Human genes 0.000 claims description 11
- 108091092562 ribozyme Proteins 0.000 claims description 11
- 238000003556 assay Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
- 239000003862 glucocorticoid Substances 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 229910003002 lithium salt Inorganic materials 0.000 claims description 6
- 159000000002 lithium salts Chemical class 0.000 claims description 6
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 6
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- 229960001727 tretinoin Drugs 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 abstract description 23
- 210000002987 choroid plexus Anatomy 0.000 abstract description 21
- 210000000981 epithelium Anatomy 0.000 abstract description 14
- 230000002207 retinal effect Effects 0.000 abstract description 8
- 210000005081 epithelial layer Anatomy 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 104
- 210000004027 cell Anatomy 0.000 description 93
- 241000282414 Homo sapiens Species 0.000 description 43
- 238000000034 method Methods 0.000 description 40
- 239000000203 mixture Substances 0.000 description 39
- 238000011282 treatment Methods 0.000 description 39
- 239000010410 layer Substances 0.000 description 31
- 102000011727 Caspases Human genes 0.000 description 29
- 108010076667 Caspases Proteins 0.000 description 29
- 229930003316 Vitamin D Natural products 0.000 description 26
- 239000006166 lysate Substances 0.000 description 26
- 239000011710 vitamin D Substances 0.000 description 26
- 235000019166 vitamin D Nutrition 0.000 description 26
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 24
- 150000003710 vitamin D derivatives Chemical class 0.000 description 24
- 229940046008 vitamin d Drugs 0.000 description 24
- 208000035475 disorder Diseases 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 201000010099 disease Diseases 0.000 description 20
- 238000009472 formulation Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 16
- 238000012545 processing Methods 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 14
- 108090000397 Caspase 3 Proteins 0.000 description 13
- 102100029855 Caspase-3 Human genes 0.000 description 13
- 101000761467 Homo sapiens Caspase-14 Proteins 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- 230000006907 apoptotic process Effects 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 210000002919 epithelial cell Anatomy 0.000 description 12
- 230000002018 overexpression Effects 0.000 description 12
- 230000000699 topical effect Effects 0.000 description 12
- 201000004681 Psoriasis Diseases 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000035515 penetration Effects 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 210000000434 stratum corneum Anatomy 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000030833 cell death Effects 0.000 description 10
- 238000003364 immunohistochemistry Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- 210000003161 choroid Anatomy 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 230000011712 cell development Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000003119 immunoblot Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000000438 stratum basale Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000006003 cornification Effects 0.000 description 7
- 208000003154 papilloma Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 239000011647 vitamin D3 Substances 0.000 description 7
- -1 vitamme D Proteins 0.000 description 7
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 6
- 108020005544 Antisense RNA Proteins 0.000 description 6
- 102000004091 Caspase-8 Human genes 0.000 description 6
- 108090000538 Caspase-8 Proteins 0.000 description 6
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003184 complementary RNA Substances 0.000 description 6
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
- 108010065038 Keratin-10 Proteins 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000004378 blood-retinal barrier Effects 0.000 description 5
- 229940106189 ceramide Drugs 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 230000037311 normal skin Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108020004491 Antisense DNA Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101000761465 Mus musculus Caspase-14 Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000005775 Parakeratosis Diseases 0.000 description 4
- 241000721454 Pemphigus Species 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 239000003816 antisense DNA Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 150000001783 ceramides Chemical class 0.000 description 4
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000000498 stratum granulosum Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000012049 topical pharmaceutical composition Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- GRFOHUBBUMAJMM-UHFFFAOYSA-N 3-(2-aminoquinolin-3-yl)-n-cyclohexyl-n-methylpropanamide Chemical compound C=1C2=CC=CC=C2N=C(N)C=1CCC(=O)N(C)C1CCCCC1 GRFOHUBBUMAJMM-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 102000004018 Caspase 6 Human genes 0.000 description 3
- 108090000425 Caspase 6 Proteins 0.000 description 3
- 108090000567 Caspase 7 Proteins 0.000 description 3
- 102100038902 Caspase-7 Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 206010067723 Skin plaque Diseases 0.000 description 3
- 206010042658 Sweat gland tumour Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 206010021198 ichthyosis Diseases 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000007876 Acrospiroma Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- 108090000426 Caspase-1 Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 206010027145 Melanocytic naevus Diseases 0.000 description 2
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 108060008539 Transglutaminase Proteins 0.000 description 2
- 206010051446 Transient acantholytic dermatosis Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000002616 endonucleolytic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 208000003906 hydrocephalus Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- HVFSJXUIRWUHRG-UHFFFAOYSA-N oic acid Natural products C1CC2C3CC=C4CC(OC5C(C(O)C(O)C(CO)O5)O)CC(O)C4(C)C3CCC2(C)C1C(C)C(O)CC(C)=C(C)C(=O)OC1OC(COC(C)=O)C(O)C(O)C1OC(C(C1O)O)OC(COC(C)=O)C1OC1OC(CO)C(O)C(O)C1O HVFSJXUIRWUHRG-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 102000003601 transglutaminase Human genes 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 229940083957 1,2-butanediol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 206010058820 Acantholysis Diseases 0.000 description 1
- 206010000349 Acanthosis Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004265 Benign familial pemphigus Diseases 0.000 description 1
- 101000983594 Bos taurus Caspase-13 Proteins 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 208000004378 Choroid plexus papilloma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 208000010837 Diabetic eye disease Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000010305 Epidermal Cyst Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 208000010368 Extramammary Paget Disease Diseases 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- 108010077716 Fas-Associated Death Domain Protein Proteins 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019043 Hair follicle tumour benign Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 1
- 108010070514 Keratin-1 Proteins 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 101000844800 Lactiplantibacillus plantarum (strain ATCC BAA-793 / NCIMB 8826 / WCFS1) D-alanyl carrier protein 1 Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010024436 Lichen spinulosus Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- XVZUMQAMCYSUMS-SIUGBPQLSA-N OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XVZUMQAMCYSUMS-SIUGBPQLSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000009193 PUVA therapy Methods 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000005214 Poroma Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038886 Retinal oedema Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 239000012721 SDS lysis buffer Substances 0.000 description 1
- 206010048810 Sebaceous hyperplasia Diseases 0.000 description 1
- 206010039785 Sebaceous naevus Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000001311 Tubular Sweat Gland Adenomas Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 206010058990 Venous occlusion Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 206010059394 acanthoma Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000018234 adnexal spiradenoma/cylindroma of a sweat gland Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000013981 benign spiradenoma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002164 blood-aqueous barrier Anatomy 0.000 description 1
- 230000004420 blood-aqueous barrier Effects 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 description 1
- 208000006571 choroid plexus carcinoma Diseases 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 201000011539 clear cell acanthoma Diseases 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 208000017563 cutaneous Paget disease Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000003481 dermatitic effect Effects 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 201000001013 eccrine acrospiroma Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 108010047963 endonuclease J Proteins 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 230000024690 epidermis development Effects 0.000 description 1
- 208000033286 epidermolytic ichthyosis Diseases 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 201000005133 hidradenoma Diseases 0.000 description 1
- 208000006634 hidrocystoma Diseases 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001329 hyperkeratotic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 201000011105 inverted follicular keratosis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000012731 long-acting form Substances 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000010904 malignant hemangioma Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000009969 melanoacanthoma Diseases 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 101150115538 nero gene Proteins 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000034004 oogenesis Effects 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 201000001063 papillary hidradenoma Diseases 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000026432 pemphigus vegetans Diseases 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- YUGCAAVRZWBXEQ-WHTXLNIXSA-N previtamin D3 Chemical compound C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)CCCC(C)C)\C=C/C1=C(C)CC[C@H](O)C1 YUGCAAVRZWBXEQ-WHTXLNIXSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 208000014271 psoriasis 5 Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000021419 recognition of apoptotic cell Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 101150031250 retm gene Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 201000010383 sebaceous gland neoplasm Diseases 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008306 shake lotion Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000006128 skin development Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 201000001019 spiradenoma Diseases 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 201000010159 squamous cell papilloma Diseases 0.000 description 1
- 208000017015 squamous papilloma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 208000000654 trichofolliculoma Diseases 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
- the present invention is based on the finding that caspase 14 is expressed in epithelial tissue such as the epidermis, the epithelial layer of the choroid plexus and the pigmented retinal layer
- the invention relates to the involvement of caspase14 in keratmocyte differentiation and in a properly functioning blood-brain barrier and blood- eye barrier
- the present invention specifically relates to nucleic acids encoding caspase-14, caspase-14 protein and modulators of caspase-14 expression, activation and bioactivity that can be used to diagnose and/or treat disorders of keratmocyte differentiation, disturbances in the blood-eye barrier and certain brain disorders
- the epidermis is a stratified squamous epithelium in which keratinocytes are organised in distinct cell layers The basal cells proliferate, but suprabasal keratinocytes withdraw from the cell cycle and progressively undergo a terminal differentiation program towards the surface of the skin
- This keratmocyte differentiation process has several similarities to apoptosis bcl-2 is downregulated in suprabasal layers of the epidermis (Lu et al , 1993, Polakowska et al , 1994) c-myc is upregulated (Gandanllas et al , 1997) and in later stages transglutaminases are activated in order to form the cornified envelope (Rice et al , 1992) In the final stage of differentiation during the formation of the cornified layer, the nucleus is condensed and eventually destroyed (McCall and Cohen, 1991 , Haake and Polakowska, 1993) Caspase family members play a central role in apopto
- Two eye-blood or blood-ocular barriers regulate exchanges between the blood and the eye the blood-aqueous barrier residing in the ciliary body and ins and the blood-retina barrier
- the latter barrier exists at two levels 1 ) at the retinal capillaries that supply the inner layers of the retina and that are non-fenestrated and do not allow the passage of macromolecules, and 2) at the freely permeable cho ⁇ ocapillaries supplying the outer layers of the retina Breakdown of the blood-ocular barriers is common during mtra-ocular disease In the anterior chamber this leads to an increase in the protein content of the aqueous, which is observed clinically as 'flare' under the slit lamp Breakdown of the blood-retina barrier at the level of the retinal capillaries and resulting in retinal oedema may occur for many reasons, of which the most important are inflammatory conditions such as uveitis, venous occlusions and diabetic retinopathy, and surgical trauma Breakdown of the blood-retina
- the current invention is based on the finding that caspase-14 expression is restricted to the suprabasal layers of the skin, the epithelial cells of the choroid plexus and the pigmented retinal layer in the eye
- the pigmented retinal layer is situated next to the vascular plexus of the choroid coat of the eye
- Immune privilege of the eye is achieved by special micro-anatomic features (blood-eye barrier), soluble factors secreted by ocular cells and by regulatory molecules constitutively expressed on the surfaces of ocular cells, such as Fas (Griffith et al 1996) Since caspase-14 is expressed in tissues where cells need to be tightly linked to one another a functional requirement for caspase-14 expression is needed in the correct formation or
- Fig. 1A shows that over-expression of caspase-14 does not induce apoptosis
- GFP and human caspase-14 expressing plasmids were transiently transfected in MCF-7 or HEK293T cells
- cells were transfected with a caspase-8 expressing plasmid
- the transfected, GFP positive population was analysed for the presence of apoptotic cells by means of light (L) and fluorescence (F) microscopy
- Caspase-8 expressing cells clearly show apoptotic morphology such as nuclear condensation
- caspase-14 expressing cells show a completely unaffected morphology
- Fig. 1 B and C demonstrate that caspase-14 is not processed when over-expressed in HEK293T or MCF-7 cells
- Fig. 3 shows expression of caspase-14 in normal skin and pso ⁇ atic plaques
- Normal human skin and skin from psoriasis patients were fixed, embedded in paraffin and sliced The sections were used for immunohistochemistry with an anti-caspase- 14 antibody
- Microscopical magnification is indicated in figures Fig.
- caspase expression pattern in normal mouse skin 100 ⁇ g of protein extracted from skin of Balb/c and C57/B16 mice was used for immunoblotting to analyse the activation of the indicated caspases (filled arrow procaspase, open arrow cleaved caspase fragments representing the large p20 subunit) Fig.
- caspase-14 is expressed in differentiated keratinocytes Lysates of undifferentiated and differentiated HaCaT cells were used for immunoblotting
- As a control for caspase-3 processing lysates were loaded derived from U937 cells treated with TNF and cycloheximide (filled arrow procaspase, open arrow processed caspase) Fig.
- FIG. 7 shows tissue of normal human plexus choroideus, plexus choroideus papilloma and plexus choroideus carcinoma that was fixed paraffin embedded and sliced Caspase-14 protein expression was detected by means of immunohistochemistry using a polyclonal ant ⁇ -caspase-14 antibody Caspase-14 is present in the epithelial cells of normal plexus choroideus, but is absent or very weakly expressed in plexus choroideus papilloma and plexus choroideus carcinoma
- the top panel of 2 pictures show a normal plexus choroideus, the middle panel of 2 pictures a plexus choroideus papilloma and the lower panel of 2 pictures a plexus choroideus carcinoma
- the pictures on the left hand side are controls, the pictures to the right hand side show caspase-14 protein expression
- Fig. 8 shows the induction of procaspase-14 expression in HaCaT cells by vitamine D, LiCI and hydrocortisome Hacat cells were grown subconfluent (top figure A) or induced to differentiate by means of post-confluent growth (bottom figure B) The cells were treated with the indicated agents for 72 h Vitamin D 3 was added to the cells 3 h before retmoic acid treatment Lysates were prepared and used for western analysis with a polyclonal ant ⁇ -caspase-14 antibody Human skin lysate was used as a control for caspase-14 expression
- 2 psonatic skin before vit D treatment
- 3 psonatic skin after vit D treatment
- - no staining
- -/+ weak or sporadic staining
- + staining
- ++ mtens staining
- ND not determined
- A, B, C, D, E, F, G are patient numbers (7 patients in total), sample numbers are indicated between brackets
- nucleic acids encoding caspase-14, caspase-14 proteins or modulators of caspase-14 bioactivity to modulate keratmocyte differentiation and/or the blood-eye barrier and/or the blood-brain barrier, and as such, to treat disorders of skin and in particular keratmocyte differentiation disorders, disturbances in the blood-eye barrier and brain disorders
- 'modulate' means control or regulation (up- or down regulation), positively or negatively, of the expression, activation or bioactivity of caspase-14 protein or of its encoding nucleotide sequence
- 'nucleic acids encoding caspase-14' refer to a polymeric form of nucleotides, either ⁇ bonucleotides or deoxynbonucleotides, encoding for caspase-14 Thus, these terms include
- modulators of the present invention are antibodies binding to caspase-14, vitamme D or homologues/de ⁇ vates (deltanoids) thereof as described in Keski-Oja J 1999 (J Lab Clin Med 133(2) 95-97) and Jones et al 1998 (Physiol Rev 78(4) 1193-1231 ), retmoic acid or homologues thereof as described in Vahlquist 1999 (Dermatology 199 suppl 1 3-11 ), transforming growth factor-beta or homologues thereof as described in Akhurst and Balmain 1999 (J Pathol 187 (1) 82-90), glucocorticoids and homologues thereof, lithium salts and calcium salts as described in Riccardi 1999 (Cell Calcium 26(3-4) 77-83)
- the term 'antibody' or 'antibodies' relates to an antibody characterized as being specifically binding to caspase-14 with said antibody being preferably a monoclonal antibody or an antigen-binding fragment thereof such as a F(ab') 2 , F(
- the normal skin consists of two layers epidermis and dermis beneath which is the subcutaneous fat
- skin There are also two types of skin, hair-bearing and non-hair-bea ⁇ ng (glabrous), e g palms and soles
- the current invention discloses that caspase-14 expression and/or activation occurs in the skin, more specifically in the epidermis, and that modulation of caspase-14 is essential for the treatment of disorders of the skin, in particular of disorders of the epidermis and/or disorders of keratmocyte differentiation, and more in particular cornification disorders
- caspase-14 may also be expressed in non-skin epithelium such as mouth epithelium
- the present invention thus also relates to the modulation of caspase-14 in the latter non-skin epithe a 'Cornification is the normal process (orthokeratosis) of skin differentiation and specifically relates to the formation of the stratum corneum
- a disorder of cornification thus relates to a defect in the latter
- Lichenoid lesions characterized by basal cell liquefaction and a 'band-like' chronic inflammatory infiltrate in the papillary dermis and dermatitic (eczematous) lesions are other groups of conditions
- Blistering eruptions or pemphigus disorders form another interrelated group of lesions in which blisters involve the epidermis and are characterized by acantholysis, i e separation of epithelial cells from each other through loss of intercellular substances and disruption of the desmosomes This results in individually separated, smooth-surfaced epidermal cells
- Two types of pemphigus are recognized 1 ) pemphigus fo aceus with its variant, Fogo Selvagem and 2) pemphigus vulga ⁇ s with its variant, pemphigus vegetans Since the expression of caspase-14 is also observed in the sebaceous glands, modulation of caspase-14 is useful in treating disease conditions affecting the pilosebaceous follicle such as follicu
- modulation of caspase-14 expression and/or activation can also be used in veterinary applications such as treatment of disorders of ectodermal extrusions such as feathers, horns and nails Moreover modulation of caspase-14 expression and/or activation can be used to treat the process of wound healing and to treat patients receiving skin transplants
- modulation of caspase-14 expression and/or activation can be used to treat the process of wound healing and to treat patients receiving skin transplants
- a high speed of skin cornification is desired to avoid infection of the skin and therefore an up-regulation of caspase-14 expression and/or activity is beneficial
- skin transplant processes it is desirable that the normal skin cornification is delayed before a successful transplantation is carried out and therefore a down-regulation of caspase-14 and/or activity is more beneficial
- in vitro skin propagation systems benefit from reduced cornification to allow better growth and expansion of the skin samples
- caspase-14 expression is specifically observed in the pigmented epithelium of the retina and that under- or over-expression of caspase-14 may result in eye-disease
- the choroids plexus is present within each of the four ventricles of the brain and is responsible for the production of cerebrospmal fluid (CSF)
- the choroids plexus has a characteristic, lobulated appearance and consists of a single continuous layer of epithelial cells overlying a vascular central core Choroidal epithelial cells are derived from the ependymal lining of the ventricles
- the choroids epithelium consists of a single continuous layer of simple cuboidal cells resting on a basal lamina
- the lateral surfaces of adjoining cells are bound by tight junctions obliterating the intercellular space and forming a barrier to extracellular movement of substances to, or from, the CSF
- This barrier function that is normally served by brain capillaries is in the choroids plexus shifted to the epithelium itself
- the present invention discloses that caspase-14 expression is specifically present (upregulated) in the cytoplasm of the choroidal epithelial cells and that modul
- the present invention also relates to the usage of nucleic acids hybridising with nucleic acids encoding for caspase-14 or fragments thereof, or molecules, such as antibodies, specifically binding to caspase-14 protein or fragments thereof for the manufacture of a diagnostic assay for skin disorders, in particular keratmocyte differentiation disorders, disorders in the blood-brain barrier and/or disorders in the blood-brain barrier
- a nucleic acid or a fragment thereof, encoding for caspase- 14 can be used as a probe for hybridisation to, for example, nucleic acids derived from a skin sample of an animal or a human
- the diagnostic method can be carried out on the protein level This can be done by using molecules that specifically bind to caspase-14 protein or a fragment thereof
- such a diagnostic method comprises the steps (i) measuring
- a unit dose will normally contain 0 01 to 50 mg for example 0 01 to 10 mg, or 0 05 to 2 mg of Caspase-14 agonist or antagonist or a pharmaceutically acceptable salt thereof
- Unit doses will normally be administered once or more than once a day, for example 2, 3, or 4 times a day, more usually 1 to 3 times a day, such that the total daily dose is normally in the range of 0 0001 to 1 mg/kg, thus a suitable total daily dose for a 70 kg adult is 0 01 to 50 mg, for example 0 01 to 10 mg or more usually 0 05 to 10 mg
- the compound or a pharmaceutically acceptable salt thereof is administered in the form of a unit-dose composition, such as a unit dose topical, oral, parenteral, or inhaled composition
- Such compositions are prepared by admixture and are suitably adapted for topical, oral, inhaled or
- Suitable fillers for use include cellulose, mannitol, lactose and other similar agents
- Suitable dismtegrants include starch, polyvmylpyrrolidone and starch derivatives such as sodium starch glycollate
- Suitable lubricants include, for example, magnesium stearate
- Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use
- Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol syrup, methyl cellulose, gelatin, hydroxyethyl
- compositions for inhalation are presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose
- the particles of active compound suitably have diameters of less than 50 microns, preferably less than 10 microns, for example between 1 and 5 microns, such as between 2 and 5 microns
- a favoured inhaled dose will be in the range of 0 05 to 2 mg, for example 0 05 to 0 5 mg, 0 1 to 1 mg or 0 5 to 2 mg
- fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle
- the active compound depending on the vehicle and the concentration, can be either suspended or dissolved
- Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing
- Parenteral solutions are normally
- a 'genetic construct' means that the coding information of caspase-14 or a functional fragment thereof is operably linked to elements known in the art that can provide transcription of the caspase-14, such as a promoter and/or enhancer sequence
- Gene therapy means the treatment by the delivery of therapeutic nucleic acids to patient's cells This is extensively reviewed in Lever and Goodfellow 1995, Br Med Bull , 51 , 1-242, Culver 1995, Ledley, F D 1995 Hum Gene Ther 6, 1 129
- To achieve gene therapy there must be a method of delivering genes to the patient's cells and additional methods to ensure the effective production of any therapeutic genes
- these are non-viral delivery and virus-mediated gene delivery
- virus-mediated gene delivery system with replication defective retroviruses to stably introduce genes into patient's cells see also further.
- human skin ceramides are the major lipid constituents of
- the skin is appealing as a target tissue for delivery of polynucleotides
- skin can be been successfully used as a site for genetic immunization (i e , immunization by administration of an antigen-encoding sequence) (see, e g , U S Pat No 5,589,466, Robinson et al 1997 Sem Immunol 9 217-83 Johnston et al 1994 Meth Cell Biol 43 353-65 Barry et al 1997 Vaccine 15 788-91 Sundaram et al 1996 Nucl Acids Res 24 1375-7, Moelling 1997 Cytokmes Cell Mol Ther 3 127-35)
- skin is an attractive target organ due to its accessibility, thereby providing one of the easiest routes of administration
- skin allows for the possibility of targeting gene expression to either differentiated or prohferative cells, depending upon the desired effect of gene product expression
- epidermal biology is relatively well-characterized at both the cellular and mole
- the topical formulations of caspase-14 include those pharmaceutical forms in which the composition is applied externally by direct contact with the skin surface to be treated
- a conventional pharmaceutical form for topical application includes a soak, an ointment, a cream, a lotion, a paste, a gel, a stick, a spray, an aerosol, a bath oil, a solution and the like
- Topical therapy is delivered by various vehicles, the choice of vehicle can be important and generally is related to whether an acute or chronic disease is to be treated
- an acute skin proliferation disease generally is treated with aqueous drying preparations
- chronic skin proliferation disease is treated with hydrat g preparations
- Soaks are the easiest method of drying acute moist eruptions
- Lotions prowder in water suspension
- solutions medications dissolved in a solvent
- a skin penetration enhancer which is dermatologically acceptable and compatible with caspase-14 can be incorporated into the formulation to increase the penetration of caspase-14 from the skin surface into epidemal keratinocytes
- a skin enhancer which increases the absorption of aminoguanidme into the skin reduces the amount of aminoguanidme needed for an effective treatment and provides for a longer lasting effect of the caspase-14 formulation
- Skin penetration enhancers are well known in the art For example, dimethyl sulfoxide (U S Pat No 3,711 ,602), oleic acid, 1 ,2- butanediol surfactant (Cooper, J Pharm Sci , 73 1153-1156 (1984)), a combination of ethanol and oleic acid or oleyl alcohol (EP 267,617), 2-ethyl-1 ,3-hexaned ⁇ ol (WO 87/03490), decyl methyl sulphoxide and Azone RTM (Hadgraft, Eur J Drug
- Levels of penetration of an caspase-14 composition can be determined by techniques known to those of skill in the art For example, radio-labeling of caspase-14, followed by measurement of the amount of radio-labelled caspase-14 absorbed by the skin enables one of skill in the art to determine levels of the composition absorbed using any of several methods of determining skin penetration of the test compound
- Publications relating to skin penetration studies include Remfenrath, W G and G S Hawkins The Weanling Yorkshire Pig as an Animal Model for Measuring Percutaneous Penetration In Swine in Biomedical Research (M E Tumbleson, Ed ) Plenum, New York, 1986, and Hawkins, G S Methodology for the Execution of In Vitro Skin Penetration Determinations In Methods for Skin Absorption B W Kemppamen and W G Reifenrath, Eds , CRC Press, Boca Raton, 1990, pp 67-80, and W G Reifenrath, Cosmetics & Toiletries 110 3-9 (1995)
- the topical formulations of this invention can have additional excipients for example, preservatives such as methylparaben, benzyl alcohol, sorbic acid or quaternary ammonium compound, stabilizers such as EDTA, antioxidants such as butylated hydroxytoluene or butylated hydroxanisole, and buffers such as citrate and phosphate
- therapeutic agents suitable for use herein are any compatible drugs that are effective for the intended purpose, or drugs that are complementary to the caspase-14 formulation
- the treatment with an formulation of this invention can be combined with other treatments such as a topical treatment with corticosteroids calcipot ⁇ ne, coal tar preparations, a systemic treatment with methotrexate, retmoids, cyclospo ⁇ n A and photochemotherapy
- the combined treatment is especially important for treatment of an acute or a severe skin proliferation disease
- the caspase-14 formulation utilized in a combination therapy may be administered
- Human skin RNA was prepared from cultured normal human keratinocytes, first strand cDNA was prepared using the Superscript Preamplification System for First strand cDNA synthesis (Gibco BRL) This keratmocyte cDNA was used to obtain a fragment containing full length human procaspase-14 or procaspase-14 ⁇ p (procaspase- 4 lacking the putative prodomain consisting of 13 ammo acids) by means of PCR technology [forward PCR primer ATAAGAATGCGGCCGCAAGCAATCCGCGGTCTTTGGAAGAGGAG; forward PCR ⁇ p primer ATAAGAATGCGGCCGCAATGTCAGGTGCCCGCCTGGCCCTA; reverse PCR primer GCTAGCTAGCCTGCAGATACAGCCGTTTCCGGAG; hcaspase-14 matching sequences are indicated in bold These Notl/Nhel digested amphcons were provided with a N-termmal flag tag and a C-termmal myc tag in a modified pCDNA3 vector (In
- HEK293T Transient transfection of HEK293T or MCF-7 and detection of apoptotic cells
- HEK293T is a human embryonal kidney carcinoma stably transfected with the SV40 T- antigen (DuB ⁇ dge et al , 1987) These cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, nonessential ammo acids, L- glutamine, and penicillin/streptomycin
- Human breast carcinoma MCF-7 cells were maintained in RPMI1640 containing 5% fetal calf serum, 5% newborn calf serum, nonessential ammo acids, L-glutamine, and penicillin/streptomycin 5x10 HEK293T or MCF-7 cells were seeded per well (6-well plate) and transiently transfected, 1 ⁇ g of total plasmid DNA, by the lipofection method (FuGene, Boehringer).
- the cells were co-transfected with pEGFP.N1 (a plasmid constitutively expressing green fluorescent protein (GFP)) and pCDNA3flag (control vector), pSVsportmC14 (Van De Craen et al 1998a), pCDNA3-mCASP-14 (Van De Craen et al., 1998a), pCDNA3-fiag-hCASP-14-myc, pcDNA3-flag-hCASP-14 ⁇ P-myc or pCAGGS-mCASP-8 (Van de Craen et al , 1998b) 24h after transfection the GFP- positive population was population was analysed for apoptotic morphology by means of fluorescence microscopy. Immunohistochemistry
- NHK normal human keratinocytes
- HaCaT or NHK cells were grown post confluence in the same medium as used for keratinocyte culture. Suspension culture was carried out as described (Watt, 1994). Briefly, after trypsinization, keratinocytes, were suspended in keratinocyte serum-free medium (10 7 per ml).
- This liquid suspension was then diluted (1.10) in keratinocyte serum-free semisolid medium containing the aforementioned supplements and 2% methylcellusose (Ald ⁇ ch, Bornem, Belgium) and incubated on 0 4% poly(2- hydroxyethylmethylacrylate) (Sigma, St Louis, MO) coated dishes Vitamin D treatment was performed in Keratinocyte Serum Free medium without insulin, thyroid hormone, and hydrocortisone because higher vitamin D anti- proliferative activity was described in the absence of insulin (Chen et al, 1995) Vitamin D was added from a stock solution of 10 "4 M per ml in absolute ethanol 1 ,25- dihydroxyvitamm D 3 was purchased from Sigma Chemical Co (St Louis MO) The cells were given fresh medium, containing the vitamin D every 24 hours Immunoblot analysis
- Transfected cells differentiated keratinocytes or skin tissue were lysed in a buffer containing 1 % NP-40, 200 mM NaCI, 10mM Tns HCI pH7-7 5, 5 mM EDTA, 10% glycerol, 1 mM PMSF, 0 1 mM aprotmm and 1 mM leupeptm
- Anti-keratin 10 and anti- human caspase- 3 were purchased from Santa-Cruz and Biosource, respectively
- Antibodies against murine caspases were raised by injecting rabbits with purified, bacterially expressed caspase preparations (Van de Craen et al , 1999)
- the anti-mu ⁇ ne caspase- 14 antibody cross-reacts with human caspase-14 on western blots as well as on immunohistochemistry staining
- caspases Upon overexpression caspases do autoprocess, thereby generating the p10 and p20 subunits, resulting in fully enzymatically active caspase eventually leading to cell death (Molmeaux et al , 1993, Kamens et al , 1995, Van de Craen et al , 1997 and 1998b)
- human caspase-14 processing was evaluated Overexpression of caspase-14 nor with or without the putative prodomam in MCF-7 or HEK293T did not result in processing (Fig B)
- caspase-3, -6 and -7 show autoprocessing resulting in the appearance of proteolytic fragments corresponding to large and small subunits, when overexpressed in HEK293T cells (Fig 1C)
- caspase-14 expression is restricted to epithelia of ectodermal origin. previously it was shown that the tissue distribution of caspase-14 mRNA is limited to the adult skin and embryo (Van de Craen et al , 1998a) To further investigate where exactly caspase-14 is expressed, we performed immunohistochemistry on embryo sections, using a polyclonal ant ⁇ -mouse-caspase-14 antibody As a negative control the stainmgs were performed with the anti-rabbit-HRP antibody only Immunostaining of 15 5 dpc embryo sections revealed that caspase-14 is expressed in the differentiated layers of the epidermis (Fig 2A), in the pigmented layer of the retina and in the epithelial cells of the choroid plexus (Fig 2B and C) Caspase- 14 is not expressed in the embryonic skin pe ⁇ derm or in the basal keratinocyte layers (stratum basale), these layers represent undifferentiated keratinocytes and contain neither the typical differentiation markers
- caspase-14 protein is only expressed in the differentiated layers of the epidermis but not in the basal layer (Fig 3).
- the expression increases gradually in the skin from the stratum spmosum towards the stratum granulosum and the stratum corneum During keratinocyte differentiation the caspase-14 expression also becomes more pronounced in the nucleus especially in the stratum granulosum In a later stage the nucleus gets expulsed, thereby reaching the final stage of differentiation resulting in the formation of the cornified layers
- the mature hairshaft and the sebaceous gland consist of differentiated keratinocytes (Hardy, 1992), and also here caspase-14 is expressed In the sweat glands, which are of dermal origin, the staining was negative 4)
- the expression of caspase-14 is drastically reduced in the skin plaques of psoriatic patients.
- Psoriasis is a common human disease with distinctive histological hallmarks including epidermal keratinocyte hyperproliferation, abnormal keratinocyte differentiation, parakeratosis and immune cell infiltration Until now it is not clear if psoriasis is caused by a defect in the keratinocyte or the recruited immune cells
- Fig 3 shows one representative patient from psonatic and non-involved skin
- the psonatic plaques show a marked decrease in the expression of caspase-14 In the parakeratotic lesions and in the abnormal, multi-layered stratum basale caspase-14 expression was seemingly absent in case of psonatic skin
- caspase-14 is not present in the stratum basale but is expressed in the differentiated layers of the epidermis, we studied whether the protein expression of caspase-14 in keratinocytes could be induced in vitro by conditions of differentiation
- a western blot experiment it was shown that cell lysates of undifferentiated HaCaT cells or normal human keratinocytes do not contain caspase-14 (Fig 5A), which was expected since these undifferentiated cells represent the stratum basale cells of the epidermis where no caspase-14 is expressed
- EE epidermal equivalents
- EE consists of several layers of differentiating KC and form a stratum corneum comparable to that of normal human epidermis in vivo and can therefore be considered an in vitro model for terminal differentiation of KC
- EE were either left submerged in culture medium or lifted to the air-liquid interface after onset of stratification Samples obtained at different timepoints were stored frozen on dry ice until further analysis
- Caspase-14 expression is reduced in papillomas and carcinomas of the choroid plexus
- caspase-14 protein expression was further analyzed upon treatment of HaCaT cells with vitamin D 3 retmoic acids LiCI, cytokmes or glucocorticoids Before treatment the cells were grown subconfluent or induced to differentiate and express procaspase-14 by means of post-confluent growth The cells that were grown
- retroviral expression vectors are developed containing wild-type caspase-14 (over-expression), a catalytically inactive caspase-14 mutant that could act as a dominant-negative form of caspase-14 (downregulation) or an antisense caspase-14 sequence (downregulation)
- the catalytically inactive mutant is obtained by modifying the catalytic important residues such as H ⁇ s89 or Cys132 (referring to the human caspase-14 sequence as previously referred to) to Ala
- retroviral vectors used for transfection of keratinocytes are EBV-based vectors such as the LZRS retroviral vector (Seitz et al , 1998) or pBabe puro (Lowell et al , 2000) These vectors are then used to transfect primary keratinocyte cultures with an > 99 % transfection efficiency The transfected keratinocytes are then used in an in vitro epidermal differentiation assay
- Skin lysates contain a caspase-14 processing activity
- lysates of undifferentiated or differentiated keratinocytes HaCaT or NHK cells
- lysates of mouse skin C57BL/6 mice
- SDS-PAGE and autoradiography The differentiated keratinocytes were obtained by growing these cells postconfluence, this condition was shown to upregulate caspase-14 expression but not processing
- RNAs for the multifunctional cytokmes ⁇ nterleuk ⁇ n-1 alpha ⁇ nterleuk ⁇ n-1 beta and tumor necrosis factor-alpha are present in adnexal tissues and in dermis of normal human skin Exp Dermatol 1995 Dec,4(6) 335-41
- Van de Craen M Van Loo G, Pype S, Van Cnekinge W, Van den brande I, Molemans F, Fiers W, Declercq W, Vandenabeele P Identification of a new caspase homologue caspase-14 Cell Death Differ 1998a Oct,5(10) 838-46 Van de Craen M, Vandenabeele P, Declercq W, Van den Brande I, Van Loo G, Molemans F, Schotte P, Van Cnekinge W, Beyaert R, Fiers W Characterization of seven murine caspase family members FEBS Lett 1997 Feb 10,403(1 ) 61-9 van de Kerkhof PC Biological activity of vitamin D analogues in the skin, with special reference to antipsonatic mechanisms Br J Dermatol 1995 May, 132(5) 675-82 Wang S, Miura M, Jung YK, Zhu H, Li E, Yuan J Murine caspase-11 , an ICE- interacting protease, is
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is based on the finding that caspase-14 is expressed in epithelial tissue such as the epidermis, the epithelial layer of the choroid plexus and the pigmented retinal layer. The invention relates to the involvement of caspase-14 in keratinocyte differentiation and in a properly functioning blood-brain barrier and blood-eye barrier. The present invention specifically relates to nucleic acids encoding caspase-14, caspase-14 protein and modulators of caspase-14 expression, activation and bioactivity that can be used to diagnose and/or treat keratinocyte differentiation disorders, disturbances in the blood-eye barrier and brain disorders.
Description
Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
Field of the invention The present invention is based on the finding that caspase 14 is expressed in epithelial tissue such as the epidermis, the epithelial layer of the choroid plexus and the pigmented retinal layer The invention relates to the involvement of caspase14 in keratmocyte differentiation and in a properly functioning blood-brain barrier and blood- eye barrier The present invention specifically relates to nucleic acids encoding caspase-14, caspase-14 protein and modulators of caspase-14 expression, activation and bioactivity that can be used to diagnose and/or treat disorders of keratmocyte differentiation, disturbances in the blood-eye barrier and certain brain disorders
Background of the invention The epidermis is a stratified squamous epithelium in which keratinocytes are organised in distinct cell layers The basal cells proliferate, but suprabasal keratinocytes withdraw from the cell cycle and progressively undergo a terminal differentiation program towards the surface of the skin This keratmocyte differentiation process has several similarities to apoptosis bcl-2 is downregulated in suprabasal layers of the epidermis (Lu et al , 1993, Polakowska et al , 1994) c-myc is upregulated (Gandanllas et al , 1997) and in later stages transglutaminases are activated in order to form the cornified envelope (Rice et al , 1992) In the final stage of differentiation during the formation of the cornified layer, the nucleus is condensed and eventually destroyed (McCall and Cohen, 1991 , Haake and Polakowska, 1993) Caspase family members play a central role in apoptosis or programmed cell death (PCD) and it was demonstrated that caspases-1 , -2, -3, -4 and -7 were expressed in cultured keratinocytes (Takahashi et al , 1998) Weil and colleagues suggested that at least caspase-3 is involved in keratmocyte differentiation and the denucleation process (Weil et al , 1999) Albeit, the terminal differentiation of keratinocytes does not seem to be a classical apoptosis since these cells don't have any membrane blebbmg or DNA fragmentation and are not phagocytosed (Polakowska et al , 1994, Gandanllas et al , 1999) Although these differences indicate that terminal differentiation is not the classical apoptosis it is still possible that both processes use a similar signal transduction pathway In addition, recent evidence l
indicated that caspases also act in differentiation processes that are associated with organelle loss such as lens fiber differentiation and oocyte maturation (Ishizaki et al 1998, McCatt et al , 1998)
Mouse and human caspase-14 (Van de Craen et al , 1998) have been 5 described These caspases have a very restricted expression pattern, this in contrast with all other caspases identified (Van de Craen et al 1997 and 1998a and b Humke et al 1998)
Skin keratinocytes play a central role in the vitamin D endocrine system Upon exposure to sunlight, the UVB component converts provitamin D3 to previtamin D3 that
10 becomes subsequently thermo-isomeπsed to vitamin D3 (Hollick, 1997) Eventually, hydroxylation leads to the formation of the hormonally active form of vitamin D3 1 ,25(OH)2 D3 (Fu et al , 1997) Keratinocytes respond to 1 ,25(OH)2 D3 with growth arrest and differentiation (Hosomi et al , 1983, Bikle and Pillai, 1993, Chen et al 1995) This observation has led to the successful use of vitamin D analogues in the i s treatment of hyperpro ferative skin diseases such as psoriasis (van de Kerkhof 1995 Fogh et al , 1997) Psoriasis, a common skin disorder with a frequency up to 2 % in many populations is characterised by keratmocyte hyperproliferation with parakeratotic differentiation (Ragaz and Ackerman, 1979, Bata-Csorgo et al , 1993) This epidermal hyperproliferation has not yet been explained on a molecular basis 0 The brain functions within a chemically well-controlled environment therefore the brain does not allow most water soluble products of the blood to enter Both the choroid plexus and the arachnoid membrane act as barriers between the blood and the cerebrospinal fluid (CSF) The choroid plexus, besides its diffusion restrictive action, actively regulates the concentration of a wide variety of molecules present in 5 the CSF The brain ventricles, containing CSF, are covered with a single layer of cells called ependymal cells This cell layer constitutes the loosely barrier between the CSF and the interstitial fluid and at the choroid plexus passes into the choroid plexus epithelial cells covering capillaries and small blood vessels Because of the tight junctions between the epithelial cells water-soluble molecules cannot diffuse freely 0 between the blood and the CSF
Two eye-blood or blood-ocular barriers regulate exchanges between the blood and the eye the blood-aqueous barrier residing in the ciliary body and ins and the blood-retina barrier The latter barrier exists at two levels 1 ) at the retinal capillaries that supply the inner layers of the retina and that are non-fenestrated and do not allow
the passage of macromolecules, and 2) at the freely permeable choπocapillaries supplying the outer layers of the retina Breakdown of the blood-ocular barriers is common during mtra-ocular disease In the anterior chamber this leads to an increase in the protein content of the aqueous, which is observed clinically as 'flare' under the slit lamp Breakdown of the blood-retina barrier at the level of the retinal capillaries and resulting in retinal oedema may occur for many reasons, of which the most important are inflammatory conditions such as uveitis, venous occlusions and diabetic retinopathy, and surgical trauma Breakdown of the blood-retina barrier at the level of Bruch's membrane and the pigmented epithelium results in accumulation of fluid between the pigmented epithelium and the neuroretma, which thus becomes detached This occasionally occurs spontaneously in the macular region, but is more often secondary to inflammation or tumours involving the choroids
Summary of the invention The current invention is based on the finding that caspase-14 expression is restricted to the suprabasal layers of the skin, the epithelial cells of the choroid plexus and the pigmented retinal layer in the eye The pigmented retinal layer is situated next to the vascular plexus of the choroid coat of the eye Hence, as in the choroid plexus in the brain, it is of extreme importance that the exchange of water-soluble molecules between the eye and the blood is tightly controlled Protection of the eye from invading pathogens or inflammatory factors is an absolute requirement for the preservation of vision (for review Streilem, 1999) Immune privilege of the eye is achieved by special micro-anatomic features (blood-eye barrier), soluble factors secreted by ocular cells and by regulatory molecules constitutively expressed on the surfaces of ocular cells, such as Fas (Griffith et al 1996) Since caspase-14 is expressed in tissues where cells need to be tightly linked to one another a functional requirement for caspase-14 expression is needed in the correct formation or functioning of these well controlled barriers, such as the skin, the brain choroid plexus and the retinal layer in the eye In addition, caspase-14 expression is drastically reduced in the skin plaques of psoπatic patients showing that caspase-14 is involved in the keratmocyte terminal differentiation program leading to normal skin development Caspase-14 is also expressed in the developing hair follicle, so having a role in hair growth or formation as well and in the sebaceous gland implicating a role in this gland functioning as well In view of the above, the present invention thus relates to the modulation of caspase-14 in order to
treat or diagnose keratmocyte differentiation disorders such as comification disorders, disturbances in the blood-eye barrier and brain disorders More specifically, the present invention discloses the usage of nucleic acids encoding caspase-14, caspase- 14 protein or fragments thereof or modulators of caspase-14 expression activation and bioactivity such as antι-caspase-14 antibodies, ribozymes, vitamme D, ret oic acid, transforming growth factor-beta (TGF-beta), glucocorticoids, lithium salts and/or calcium salts to treat or diagnose the latter diseases
Brief description of figures and table Fig. 1A shows that over-expression of caspase-14 does not induce apoptosis
GFP and human caspase-14 expressing plasmids were transiently transfected in MCF-7 or HEK293T cells As a control for apoptotic cell death, cells were transfected with a caspase-8 expressing plasmid The transfected, GFP positive population was analysed for the presence of apoptotic cells by means of light (L) and fluorescence (F) microscopy Caspase-8 expressing cells clearly show apoptotic morphology such as nuclear condensation In contrast, caspase-14 expressing cells show a completely unaffected morphology
Fig. 1 B and C demonstrate that caspase-14 is not processed when over-expressed in HEK293T or MCF-7 cells B) HEK293T cells or MCF-7 cells were transfected with different plasmids expressing munne or human caspase-14 (see also Fig 1A) After 24h, lysates were prepared and these were subjected to SDS-PAGE, electroblotted and revealed with a polyuυnai di ιtι-odbpdse-14 antibody C) Caspase-3, -6 or -7 were overexpressed in HEK293T cells Lysates were prepared after 24h and used for immunoblotting with the corresponding anti-caspase antibodies (filled arrow = procaspase, open arrow = large and small subunits of processed caspase) Fig. 2 demonstrates the expression of caspase-14 in the mouse embryo Immunohistochemistry, with an antι-caspase-14 antibody was performed on transversal sections of 15,5 dpc Balb/c mice A) expression in the skin, B) expression in the eye, C) expression in the brain (D = dorsal side, dk = differentiated keratinocytes, ec = epithelial layer of the choroid plexus, ep = epidermis, hi = premature hairbulb, h2 = maturing hairbulb, I = lens, n = nucleus, nl = neural layer of the retina, p = penderm, pi = pigmental layer of the retina, sb = stratum basale, V =
ventral side, vc = vascular plexus of the eye choroid)
Fig. 3 shows expression of caspase-14 in normal skin and psoπatic plaques Normal human skin and skin from psoriasis patients were fixed, embedded in paraffin and sliced The sections were used for immunohistochemistry with an anti-caspase- 14 antibody A) Normal skin B) Skin from a psoriasis patient (ep = epidermis, sb = stratum basale, sc = stratum corneum, sg = stratum granulosum, ss = stratum spinosum, n = nucleus, pp = psonatic plaque) Microscopical magnification is indicated in figures Fig. 4 shows caspase expression pattern in normal mouse skin 100 μg of protein extracted from skin of Balb/c and C57/B16 mice was used for immunoblotting to analyse the activation of the indicated caspases (filled arrow procaspase, open arrow cleaved caspase fragments representing the large p20 subunit) Fig. 5 demonstrates that caspase-14 is expressed in differentiated keratinocytes Lysates of undifferentiated and differentiated HaCaT cells were used for immunoblotting A) Differentiation was induced by growing cells postconfluent and the lysates were used for immunoblotting with the indicated antibodies B) Normal Human Keratinocytes were grown in suspension Lysates were made at the indicated antibodies and used for immunodetection of caspase-14 As a control for caspase-3 processing lysates were loaded derived from U937 cells treated with TNF and cycloheximide (filled arrow procaspase, open arrow processed caspase) Fig. 6 shows the vitamin D dependent up-regulation of caspase-14 expression A) HaCaT cells were treated with no, 10 10M, 10 9M, 108M, 10 7M or 106M vitamin D and lysed after 72h The lysates were used for immunoblotting with antibodies as indicated B) Differentiation of HaCaT cells was induced through addition of 107M vitamin D Lysates were made at the indicated time-points and used for immunoblotting with the indicated antibodies As a control for caspase-3 processing lysates were loaded derived from U937 cells treated with TNF and cycloheximide (filled arrow procaspase, open arrow processed caspase) Fig. 7 shows tissue of normal human plexus choroideus, plexus choroideus papilloma and plexus choroideus carcinoma that was fixed paraffin embedded and sliced Caspase-14 protein expression was detected by means of immunohistochemistry using a polyclonal antι-caspase-14 antibody Caspase-14 is present in the epithelial cells of normal plexus choroideus, but is absent or very weakly expressed in plexus
choroideus papilloma and plexus choroideus carcinoma The top panel of 2 pictures show a normal plexus choroideus, the middle panel of 2 pictures a plexus choroideus papilloma and the lower panel of 2 pictures a plexus choroideus carcinoma The pictures on the left hand side are controls, the pictures to the right hand side show caspase-14 protein expression
Fig. 8 shows the induction of procaspase-14 expression in HaCaT cells by vitamine D, LiCI and hydrocortisome Hacat cells were grown subconfluent (top figure A) or induced to differentiate by means of post-confluent growth (bottom figure B) The cells were treated with the indicated agents for 72 h Vitamin D3 was added to the cells 3 h before retmoic acid treatment Lysates were prepared and used for western analysis with a polyclonal antι-caspase-14 antibody Human skin lysate was used as a control for caspase-14 expression
Table 1 shows the effect of vitamin D treatment on caspase-14 expression in human psoπatic plaques in stratum basale, stratum spmosum, stratum granulosum and stratum corneum 1 = control skin, 2 = psonatic skin before vit D treatment, 3 = psonatic skin after vit D treatment, - = no staining, -/+ = weak or sporadic staining, + = staining, ++ = mtens staining, ND = not determined, A, B, C, D, E, F, G are patient numbers (7 patients in total), sample numbers are indicated between brackets
Detailed description of the invention
It is an object of the present invention to modulate the formation or functioning of well controlled barriers such as skin, the brain choroid plexus or retinal layer in the eye based on caspase-14 expression It is thus an aim of the present invention to use nucleic acids encoding caspase-14, caspase-14 proteins or modulators of caspase-14 bioactivity to modulate keratmocyte differentiation and/or the blood-eye barrier and/or the blood-brain barrier, and as such, to treat disorders of skin and in particular keratmocyte differentiation disorders, disturbances in the blood-eye barrier and brain disorders The term 'modulate' means control or regulation (up- or down regulation), positively or negatively, of the expression, activation or bioactivity of caspase-14 protein or of its encoding nucleotide sequence The terms 'nucleic acids encoding caspase-14' refer to a polymeric form of nucleotides, either πbonucleotides or deoxynbonucleotides, encoding for caspase-14 Thus, these terms include double- and single-stranded DNA, and RNA They also include known types of modifications, for example, methylation, ' caps" substitution of one or more of the naturally occurring
nucleotides with an analogue Specifically, the nucleic acid sequences of the invention comprise a coding sequence for caspase-14 as disclosed in PCT/EP99/04939 A "coding sequence" is a nucleotide sequence that is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences A coding sequence can include, but is not limited to mRNA, cDNA, recombinant nucleotide sequences or genomic DNA Also fragments of 'nucleic acids encoding caspase-14' are part of the present invention These fragments can contain 5, 10, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more contiguous nucleotides and must be capable of modulating keratmocyte differentiation and/or the blood-eye barrier and/or the blood-brain barrier The terms 'modulators of caspase-14 bioactivity' refer in principle to any agent or molecule that has an effect on the amount of caspase-14 protein, the stability of caspase-14 or on the bioactivity of caspase-14 protein in any cell By 'agent or molecule' it is meant peptides, proteins, carbohydrates or any other small organic or an-organic compound The present invention thus relates to molecules that can be used to neutralize the activity of caspase-14 by interfering with its synthesis (i e transcription) and/or its translation In this respect, it is clear that some modulators may act directly on the above-mentioned regulatory sequences such as the caspase-14 promotor, or on mRNA encoding caspase-14, or on the translated, non-bioactive caspase-14 polypeptide or on the bioactive caspase-14 protein whereas other modulators, such as vitamme D, act indirectly on the latter targets Some examples of 'modulators of caspase-14' are antagonists neutralizing caspase-14 bioactivity, (small) molecules binding on the promoter region of caspase-14 so that binding of a transcription factor on said promotor is inhibited, (small) molecules binding to said transcription factor so that again binding to the caspase-14-promoter is inhibited, anti-sense RNA and DNA molecules and ribozymes that function to inhibit transcription or translation of caspase-14, and molecules interfering with the processing of the caspase-14 polypeptide and, as such, the activation of the caspase- 14 polypeptide The anti-sense RNA and DNA molecules and ribozymes as mentioned above function to inhibit the translation of caspase-14 mRNA and/or to affect transcription of caspase-14 DNA into caspase mRNA For example, anti-sense RNA and DNA molecules that directly block the translation of mRNA bind to said mRNA and as such prevent protein translation Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA The mechanism of πbozyme action involves sequence specific hybridization of the πbozyme molecule to complementary
target RNA, followed by an endonucleolytic cleavage Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of caspase-14 RNA sequences Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites that include the following sequences, GUA, GUU and GUC Once identified, short RNA sequences of between 15 and 20 πbonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the o gonucleotide sequence unsuitable The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using nbonuclease protection assays Both anti-sense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules These include techniques for chemically synthesizing oligodeoxyπbonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule Such DNA sequences may be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters Alternatively, antisense cDNA constructs that synthesize anti-sense RNA constitutively or mducible depending on the promoter used, can be introduced stably into cell lines
More specific examples of modulators of the present invention are antibodies binding to caspase-14, vitamme D or homologues/deπvates (deltanoids) thereof as described in Keski-Oja J 1999 (J Lab Clin Med 133(2) 95-97) and Jones et al 1998 (Physiol Rev 78(4) 1193-1231 ), retmoic acid or homologues thereof as described in Vahlquist 1999 (Dermatology 199 suppl 1 3-11 ), transforming growth factor-beta or homologues thereof as described in Akhurst and Balmain 1999 (J Pathol 187 (1) 82-90), glucocorticoids and homologues thereof, lithium salts and calcium salts as described in Riccardi 1999 (Cell Calcium 26(3-4) 77-83) The term 'antibody' or 'antibodies' relates to an antibody characterized as being specifically binding to caspase-14 with said antibody being preferably a monoclonal antibody or an antigen-binding fragment thereof such as a F(ab')2, F(ab) or single chain Fv type, or, any type of recombinant antibody derived thereof The monoclonal antibodies of the invention can for instance be produced by any hybndoma liable to be formed according to classical methods
from splenic cells of an animal, particularly of a mouse or rat immunized against caspase-14, and of cells of a myeloma cell line, and to be selected by the ability of the hybndoma to produce the monoclonal antibodies recognizing caspase-14 which have been initially used for the immunization of the animals The monoclonal antibodies according to this invention may also be humanized versions of the mouse monoclonal antibodies made by means of recombinant DNA technology, departing from the mouse and/or human genomic DNA sequences coding for H and L chains or from cDNA clones coding for H and L chains Alternatively the monoclonal antibodies according to this invention may be human monoclonal antibodies Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) re-population of severe combined immune deficiency (SCID) mice as described in PCT/EP 99/03605 or by using transgenic non-human animals capable of producing human antibodies as described in US patent 5,545,806 Also fragments derived from these monoclonal antibodies such as Fab, F(ab)'2 and scFv ("single chain variable fragment"), providing they have retained the original binding properties, form part of the present invention Such fragments are commonly generated by, for instance, enzymatic digestion of the antibodies with papam, pepsin, or other proteases Furthermore it is also well known in the art that monoclonal antibodies, or fragments thereof can be modified for various uses For example, the antibodies of the present invention can be labelled with an appropriate label of the enzymatic, fluorescent or radioactive type It should also be clear that the 'antibodies' of the present invention also include polyclonal antisera prepared against caspase-14 The present invention thus relates to the usage of nucleic acids encoding caspase-14, caspase-14 protein, modulators of caspase-14 expression, modulators of caspase-14 activation and/or bioactivity for the manufacture of a medicament for treating skin disorders, in particular keratmocyte differentiation disorders, disturbances in the blood- eye barrier and brain disorders It should also be clear that fragments and vaπants/homologues of said modulators that are capable of modulating keratmocyte differentiation and/or the blood-eye barrier and/or the blood-brain barrier are part of the present invention
With respect to skin disorders it should be clear the normal skin consists of two layers epidermis and dermis beneath which is the subcutaneous fat There are also two types of skin, hair-bearing and non-hair-beaπng (glabrous), e g palms and soles The current invention discloses that caspase-14 expression and/or activation occurs in
the skin, more specifically in the epidermis, and that modulation of caspase-14 is essential for the treatment of disorders of the skin, in particular of disorders of the epidermis and/or disorders of keratmocyte differentiation, and more in particular cornification disorders However, it should be clear that caspase-14 may also be expressed in non-skin epithelium such as mouth epithelium The present invention thus also relates to the modulation of caspase-14 in the latter non-skin epithe a 'Cornification is the normal process (orthokeratosis) of skin differentiation and specifically relates to the formation of the stratum corneum A disorder of cornification thus relates to a defect in the latter process and can be arbitrarily subdivided in parakeratotic and hyperkeratotic disorders Hereditary conditions characterized by a cornification disorder are (1 ) ichthyosis ('fish skin' disease) referring to a complex group of conditions all characterized by generalized, non-inflammatory flaky and scaly, thickened skin (2) bullous ichthyoform erythroderma referring to solitary or localized lesions identical to epidermolytic hyperkeratosis present in the skin (3) Darier disease or follicular keratosis, (4) Hailey-Hailey (benign familial chronic pemphigus), (5) Grover disease (transient acantholytic dermatosis), (6) epidermolysis bullosa (mechano-bullous diseases) and (7) Mi aria (M crystalline, M rubra, M profunda) In addition there is a group of conditions, called psoπasiform lesions, in which the pathological features are characterized by focal lamellar parakeratosis regular acanthosis, prolongation of rete ridges and squirting papillae Psoriasis is an example of such a condition and the present invention discloses that caspase-14 expression in psonatic skin is drastically down-regulated So strategies to up-regulate caspase-14 expression may prove to have an important therapeutic contribution to diseases involving parakeratosis such as psoriasis
Lichenoid lesions characterized by basal cell liquefaction and a 'band-like' chronic inflammatory infiltrate in the papillary dermis and dermatitic (eczematous) lesions are other groups of conditions Blistering eruptions or pemphigus disorders form another interrelated group of lesions in which blisters involve the epidermis and are characterized by acantholysis, i e separation of epithelial cells from each other through loss of intercellular substances and disruption of the desmosomes This results in individually separated, smooth-surfaced epidermal cells Two types of pemphigus are recognized 1 ) pemphigus fo aceus with its variant, Fogo Selvagem and 2) pemphigus vulgaπs with its variant, pemphigus vegetans
Since the expression of caspase-14 is also observed in the sebaceous glands, modulation of caspase-14 is useful in treating disease conditions affecting the pilosebaceous follicle such as follicu tis, acne vulgaπs, keratosis pilaπs, lichen spinulosus, rosacea which is a common condition with a variable clinical appearance including facial flushing, erythema, papules, and pustules, pitynasis rubra pilaπs, pityπasis rubra pilaπs, alopecia including alopecea areata and scarring alopecias Caspase-14 modulation may also be essential for diagnosing and/or treating tumours of the skin such as epidermal naevi organoid naevus (naevus sebaceous of Jadassohn), seborrhoeic keratosis (basal cell papilloma), melanoacanthoma, inverted follicular keratosis, squamous cell papilloma, clear cell acanthoma, epidermal cysts solar keratosis bowen disease, squamous cell carcinoma keratoacanthoma basal cell carcinoma, basosquamous cancer, lentigo, melanocytic naevus, malignant melanoma, eccπne gland tumours such as eccπne poroma, syπngoma, cylindroma, eccπne hidrocystoma, eccπne spiradenoma, hidradenoma and sweat gland carcinoma, tumours of apocrme glands and the pilosebaceous unit such as hidradenoma papilliferum, syπngocystadenoma papilrferum, apocrme carcinoma, extra-mammary Paget disease, trichofolliculoma, tπchoepithelioma, pilomatixoma, tπchilemmoma, sebaceous gland neoplasms and sebaceous hyperplasia Thus, caspase-14 expression may also be involved in the development of keratmocyte tumors and a protocol can be developed to up-regulate the caspase-14 expression in tumor cells so that denucleation and a subsequent eradication of said tumor cells occurs
Excessive cornification can also take place in the multi-layer epithelium of the mouth the airway and the vagina so that modulation of caspase-14 expression and/or activation also assists in curing these disease processes
It is clear that modulation of caspase-14 expression and/or activation can also be used in veterinary applications such as treatment of disorders of ectodermal extrusions such as feathers, horns and nails Moreover modulation of caspase-14 expression and/or activation can be used to treat the process of wound healing and to treat patients receiving skin transplants For example in wound healing a high speed of skin cornification is desired to avoid infection of the skin and therefore an up-regulation of caspase-14 expression and/or activity is beneficial On the other hand in skin transplant processes it is desirable that the normal skin cornification is delayed before a successful transplantation is carried
out and therefore a down-regulation of caspase-14 and/or activity is more beneficial Also in vitro skin propagation systems benefit from reduced cornification to allow better growth and expansion of the skin samples
With respect to disturbances in the blood-eye barrier it is clear from the present invention that caspase-14 expression is specifically observed in the pigmented epithelium of the retina and that under- or over-expression of caspase-14 may result in eye-disease A non-limited list of such diseases which are due to a malfunctioning of the blood-retina barrier or where a reduction in blood-retina barrier function takes place include (1 ) glaucoma, (2) diseases, due to various infective agents, such as conjunctivitis (3) uveitis (4) Fuchs heterochromic iπdocyclitis (5) sympathetic ophthalmrtis, (6) lens-induced endophtalmitis, (7) diseases of the retina such as diabetic eye disease, retmopathy of prematurity, inherited retinal degeneration, retmitis pigmentosa, age-related macular degeneration, senile macular degeneration and disciform degeneration, (8) cataract, (9) mtra-ocular tumours such as malignant melanomas, hemangiomas and retinoblastomas (10) multiple sclerosis, (11 ) ischemia, and (12) AIDS
With regard to brain disorders, it is clear that the choroids plexus is present within each of the four ventricles of the brain and is responsible for the production of cerebrospmal fluid (CSF) The choroids plexus has a characteristic, lobulated appearance and consists of a single continuous layer of epithelial cells overlying a vascular central core Choroidal epithelial cells are derived from the ependymal lining of the ventricles The choroids epithelium consists of a single continuous layer of simple cuboidal cells resting on a basal lamina The lateral surfaces of adjoining cells are bound by tight junctions obliterating the intercellular space and forming a barrier to extracellular movement of substances to, or from, the CSF This barrier function that is normally served by brain capillaries is in the choroids plexus shifted to the epithelium itself The present invention discloses that caspase-14 expression is specifically present (upregulated) in the cytoplasm of the choroidal epithelial cells and that modulation of caspase-14 expression and/or activation is involved in the modulation of the barrier function of the choroids plexus In man the normal pressure of CSF as measured in the recumbent position by lumbar puncture varies from 25-70 mm water in infants and from 65-195 mm water (5-15 mm Hg) in adults Elevations of this CSF pressure may be an indication of a neural pathology like a tumor such as a papilloma or a carcinoma (see examples) An excess in CSF mtracranially can result in
hydrocephalus and an excess in CSF pressure can also be the result of head injury, meningitis or idiopathic causes Untreated, elevated CSF pressure leads to progressive neurological dysfunction, coma, and eventually death A reduction in blood-brain barrier takes also place in the following diseases cerebral malaria traumatic brain injury acute encephalopathy and encephalitis related to influenza virus infection, multiple sclerosis, acute colitis AIDS cerebral ischemie Alzheimer s disease and acute hypertension The modulation of caspase-14 expression can thus be used to treat the above-described disorders Modulation of the choroids epithelial barrier through caspase-14 modulation can also be used for the treatment of neuronal disorders such as Alzheimer s disease or Parkinson s disease where it is necessary that a medicament efficiently crosses the blood-brain barrier or where it is necessary that the crossing of the blood-bram-barπer of a compound or medicament has to be inhibited Thus, in certain instances when medication is required, it might be desirable that said barrier is (temporally) less stringent in order to let penetrate medicaments having a therapeutic action into the brain and/or eye respectively
The present invention also relates to the usage of nucleic acids hybridising with nucleic acids encoding for caspase-14 or fragments thereof, or molecules, such as antibodies, specifically binding to caspase-14 protein or fragments thereof for the manufacture of a diagnostic assay for skin disorders, in particular keratmocyte differentiation disorders, disorders in the blood-brain barrier and/or disorders in the blood-brain barrier Thus a nucleic acid or a fragment thereof, encoding for caspase- 14 can be used as a probe for hybridisation to, for example, nucleic acids derived from a skin sample of an animal or a human It can be also expected that mutations in the caspase-14 gene may lead to skin disorders and that these mutations can be detected by hybridisation with the natural occurring caspase-14 gene or with an ohgonucleotide comprising said mutation Alternatively the diagnostic method can be carried out on the protein level This can be done by using molecules that specifically bind to caspase-14 protein or a fragment thereof Typically such a diagnostic method comprises the steps (i) measuring the level of caspase-14 in an appropriate skin sample derived from an animal or a human that is to be diagnosed, and then (n) comparing the level found with the corresponding level (normal level, normal concentration range) for apparently healthy animals or humans (normal individuals) If the level found deviates from the normal level this is an
indication that the animal or human suffers from some abnormal condition of skin disorder A raised level will be indicative of hyperkeratmization while subnormal levels may be found in connection with parakeratotic syndromes such as psoriasis The measurement of caspase-14 protein can in principle be performed by any method that provides the satisfactory sensitivity, precision, specificity etc It is believed that immunoassays are the most preferred methods Immunoassays comprise bringing the sample suspected of containing an abnormal level of caspase-14 in contact with an antibody specific for caspase-14 (antι-caspase-14 antibody) in an assay medium under conditions permitting formation of an immune complex comprising caspase-14 and the antι-caspase-14 antibody The complex formed is thereafter determined by per se known methods to give a quantitative or qualitative measure of the caspase-14 level in the assay medium that in turn is a measure of the caspase-14 level in the sample In these types of assays the complex as such may be measured or it may be measured by aid of a biospecific, affinity reactant labelled with an analytically detectable substance (label), said reactant (and its label) being capable of becoming specifically incorporated into the complex Examples of suitable biospecific affinity reactants that can be labelled are antι-caspase-14 antibodies, caspase-14 as such, anti-antibodies (anti-anti- caspase-14 antibody) directed against constant regions of an antibody that is present in the complex formed, Proteins A and G etc Examples of detectable substances (labels) that may be used are luminescers, chromophors fluorophors, enzymes, enzyme substrates, cofactors, coenzymes, radioactive isotopes, particles (metallic or non-metallic), biotm (detected by its reaction with avidin) etc Some labels change their signal when becoming incorporated into the immune complex while others do not The former type of labels provides homogeneous immune assays in which there is no need to separate the label incorporated into the complex from the label not incorporated The latter type of labels demands the separation to be carried out, for instance by insolubilizmg the complex in which the label is or is to be incorporated (heterogeneous assays) In order to achieve an insolubilized complex that contains the label, precipitating agents such as polyethylene glycol and insolubilized and msolubilizable biospecific affinity reactants binding to the complex may be used Of course this latter type shall not insolubihze the labelled biospecific affinity reactant as such The artisan in the field is capable of selecting the appropriate immunoassay protocols, for instance homogeneous or heterogeneous variants, order and type of addition and incubation steps etc The mam point is that the
amount of reactants added must be such that the amount of label incorporated into the complex or not incorporated into the complex will reflect the caspase-14 level in the sample Normal assay conditions are aqueous media with or without non-disturbing water-miscible co-solvents, temperatures within 0-40 °C and pH-values within 4-10 The antι-caspase-14 antibody used may be prepared by standard techniques well- known for other antibodies The term encompasses polyclonal as well as monoclonal antibodies and antibodies produced by recombinant techniques The term anti- caspase-14 antibody means an antibody preparation reacting specifically with caspase-14, such as in monomeric forms, caspase-14 as included in dι-, multi or heteromeric forms and/or fragments of monomeric caspase-14 exhibiting caspase-14 unique determinants and epitopes The present invention discloses that the above- described molecules can be used as a medicament for treatment of diseases as described above or can be used to treat said diseases In this respect, the present invention also relates to a pharmaceutical composition comprising modulators of caspase-14 bioactivity, nucleic acids encoding caspase-14 and/or caspase-14 protein It should be clear that the therapeutic method of the present invention against for example skin disorders can also be used in combination with any other skin therapy known in the art such as PUVA-therapy or retmoic acid treatment The term 'medicament to treat' relates to a composition comprising molecules as described above and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably) to treat diseases as indicated above The administration of a compound, an antagonist or agonist of the caspase-14 or a pharmaceutically acceptable salt thereof may be by way of topical, oral inhaled or parenteral administration The active compound may be administered alone or preferably formulated as a pharmaceutical composition
An amount effective to treat the disorders described above depends on the usual factors such as the nature and severity of the disorders being treated and the weight of the mammal However, a unit dose will normally contain 0 01 to 50 mg for example 0 01 to 10 mg, or 0 05 to 2 mg of Caspase-14 agonist or antagonist or a pharmaceutically acceptable salt thereof Unit doses will normally be administered once or more than once a day, for example 2, 3, or 4 times a day, more usually 1 to 3 times a day, such that the total daily dose is normally in the range of 0 0001 to 1 mg/kg, thus a suitable total daily dose for a 70 kg adult is 0 01 to 50 mg, for example 0 01 to 10 mg or more usually 0 05 to 10 mg It is greatly preferred that the compound
or a pharmaceutically acceptable salt thereof is administered in the form of a unit-dose composition, such as a unit dose topical, oral, parenteral, or inhaled composition Such compositions are prepared by admixture and are suitably adapted for topical, oral, inhaled or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, mjectable and mfusable solutions or suspensions or suppositories or aerosols Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents fillers diluents tablettmg agents, lubricants, dismtegrants, colourants, flavourings and wetting agents The tablets may be coated according to well-known methods in the art
Suitable fillers for use include cellulose, mannitol, lactose and other similar agents Suitable dismtegrants include starch, polyvmylpyrrolidone and starch derivatives such as sodium starch glycollate Suitable lubricants include, for example, magnesium stearate Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate These solid oral compositions may be prepared by conventional methods of blending, filling, tablettmg or the like Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers Such operations are, of course, conventional in the art Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia, non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol, preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid and if desired conventional flavouring or colouring agents Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating
Preferably, compositions for inhalation are presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose In
such a case the particles of active compound suitably have diameters of less than 50 microns, preferably less than 10 microns, for example between 1 and 5 microns, such as between 2 and 5 microns A favoured inhaled dose will be in the range of 0 05 to 2 mg, for example 0 05 to 0 5 mg, 0 1 to 1 mg or 0 5 to 2 mg For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle The active compound, depending on the vehicle and the concentration, can be either suspended or dissolved Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound Where appropriate, small amounts of bronchodilators for example sympathomimetic amines such as isoprenalme, isoethaπne, salbutamol, phenylephπne and ephedπne, xanthine derivatives such as theophyllme and aminophylline and corticosteroids such as prednisolone and adrenal stimulants such as ACTH may be included As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned The present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of herein described disorders which comprises a molecule or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and, if required, a pharmaceutically acceptable carrier thereof Another pharmaceutically acceptable composition is an inhalation composition, suitably in unit dosage form Yet another pharmaceutical acceptable composition for treatment of skin disorders is a topical composition, suitable in unit dosage form
Genetic constructs of caspase-14 or functional fragments thereof can also be used in gene therapy A 'genetic construct' means that the coding information of caspase-14 or a functional fragment thereof is operably linked to elements known in the art that can provide transcription of the caspase-14, such as a promoter and/or enhancer
sequence Gene therapy means the treatment by the delivery of therapeutic nucleic acids to patient's cells This is extensively reviewed in Lever and Goodfellow 1995, Br Med Bull , 51 , 1-242, Culver 1995, Ledley, F D 1995 Hum Gene Ther 6, 1 129 To achieve gene therapy there must be a method of delivering genes to the patient's cells and additional methods to ensure the effective production of any therapeutic genes There are two general approaches to achieve gene delivery, these are non-viral delivery and virus-mediated gene delivery As an example, but not limited to this is the use of a virus-mediated gene delivery system with replication defective retroviruses to stably introduce genes into patient's cells (see also further) In human skin ceramides are the major lipid constituents of the stratum corneum Together with the neutral lipids, they form broad laminated intercellular sheets and play a crucial role in the skin barrier function Ceramide-containing dermato-cosmetic products have been suggested for use in dermato-cosmetic applications such as a restoration of a disturbed skin barrier function Also in gene therapy ceramides can be added to compounds activating the activity of caspase-14 or ceramides can be added to vectors comprising nucleic acids encoding caspase-14 The application of ceramides can facilitate the topical administration
The skin, particularly the epidermis, is appealing as a target tissue for delivery of polynucleotides For example, skin can be been successfully used as a site for genetic immunization (i e , immunization by administration of an antigen-encoding sequence) (see, e g , U S Pat No 5,589,466, Robinson et al 1997 Sem Immunol 9 217-83 Johnston et al 1994 Meth Cell Biol 43 353-65 Barry et al 1997 Vaccine 15 788-91 Sundaram et al 1996 Nucl Acids Res 24 1375-7, Moelling 1997 Cytokmes Cell Mol Ther 3 127-35) Second, skin is an attractive target organ due to its accessibility, thereby providing one of the easiest routes of administration Moreover, because it is a stratified epithelium, skin allows for the possibility of targeting gene expression to either differentiated or prohferative cells, depending upon the desired effect of gene product expression In addition, epidermal biology is relatively well-characterized at both the cellular and molecular levels For example, the regulatory sequences of the keratins have been used to express a variety of exogenous genes in the epidermis of transgenic mice, and are readily adaptable for expression in other organisms (Greenhalgh et al 1994 J Invest Dermatol 103 63S-69S, Vassar et al 1991 Genes Dev 5 714-27, Bailleul et al 1990 Cell 62 697-708) Further to the present invention it would be desirable to use for example, but not-
limiting, a recombinant adenoviral vector wherein the expression of caspase-14 is under control of a strong, constitutive or mducible promoter which could be used to treat parakeratotic skin diseases such as psoriasis Alternatively a recombinant viral vector could be constructed where a dominant negative caspase-14 or an antisense construct of caspase-14 or a ribozyme against caspase-14 is under control of a strong promoter The latter recombinant vector could be used to treat for example skin disorders of hyperkeratmization
Conventional methods for delivery of polynucleotides for expression in the skin include invasive, semi-invasive, or non-invasive methods Invasive methods involve breaking the skin or otherwise disrupting or bypassing the epidermal barrier Conventional invasive methods include needle injection (U S Pat No 5 589 466, Masayuki et al 1996 FEMS Immunol Med Microbiol 14 221-30, Ciernik et al 1996 Hum Gene Ther 7 893-9), particle bombardment ("gene gun," Vahlsing et al 1994 J Immuol Meth 175 11-22, Cheng et al 1993 Proc Natl Acad Sci USA 90 4455-9, Sundaram et al 1996 Nucl Acids Res 24 1375-7, Johnston et al 1994 Meth Cell Biol 43 353-65), and jet injection (Furth et al 1995 Molec Biotech 4 121-7) Expression of an exogenous DNA has also been accomplished by direct application of DNA or DNA-hposome complexes to mcisional wounds (Sun et al 1997 J Invest Dermatol 108 313-8) Semi- invasive methods involve permeabihzation of the epithelium through either mechanical or chemical means For example, one successful semi-invasive method involves the application of a pulsed electric field to the skin (Zhang et al 1996 Biochem Biophys Res Commun 220 633-6) The invasive and semi-invasive methods generally deliver the polynucleotide in the form of naked DNA (see e g , U S Pat No 5,589,466) Non- mvasive methods include topical application of a DNA-containmg formulation that contains transfection-facilitatmg molecules Examples of such formulations include liposomes (Li et al 1995 Nature Med 1 705-6, Alexander et al 1995 Human Mol Genet 4 2279-85) In general, conventional non-invasive methods involve pretreatment of the skin to remove hair (e g , by shaving and/or use of a depilatory) (Li et al 1995 Nature Med 1 705-6, Alexander et al 1995 Human Mol Genet 4 2279-85) Although conventional methods hold great promise for delivery of gene products to the skin of local and systemic effects, the more complicated the delivery method or the delivery formulation, the more difficult application of these methods and formulations will be in the field For example, a genetic construct comprising the caspase-14 polynucleotide sequence preferred for use in the field would be one that requires no
special equipment, such as instruments for breaking the skin to deliver the DNA, and further involves no special formulation that might require special handling Recent methods for delivery of polynucleotides to skin cells do not require special formulations or invasive procedures to facilitate delivery of the genetic material into skin cells An example of such a method is fully described in US 6,087,341
The topical formulations of caspase-14 (polynucleotide constructs or the purified caspase-14 protein) include those pharmaceutical forms in which the composition is applied externally by direct contact with the skin surface to be treated A conventional pharmaceutical form for topical application includes a soak, an ointment, a cream, a lotion, a paste, a gel, a stick, a spray, an aerosol, a bath oil, a solution and the like Topical therapy is delivered by various vehicles, the choice of vehicle can be important and generally is related to whether an acute or chronic disease is to be treated As an example, an acute skin proliferation disease generally is treated with aqueous drying preparations, whereas chronic skin proliferation disease is treated with hydrat g preparations Soaks are the easiest method of drying acute moist eruptions Lotions (powder in water suspension) and solutions (medications dissolved in a solvent) are ideal for hairy and intertπginous areas Ointments or water-m-oil emulsions, are the most effective hydratmg agents, appropriate for dry scaly eruptions, but are greasy and depending upon the site of the lesion sometimes undesirable As appropriate, they can be applied in combination with a bandage, particularly when it is desirable to increase penetration of the caspase-14 composition into a lesion Creams or oil-in- water emulsions and gels are absorbable and are the most cosmetically acceptable to the patient (Guzzo et al, in Goodman & Gilman's Pharmacological Basis of Therapeutics, 9 sup th Ed , p 1593-15950 (1996)) Cream formulations generally include components such as petroleum, lanolin, polyethylene glycols, mineral oil, glycerin, isopropyl palmitate, glyceryl stearate, cetearyl alcohol, tocopheryl acetate, isopropyl myπstate, lanolin alcohol, simethicone, carbomen, methylchloπsothiazolinone, methylisothiazolinone, cyclomethicone and hydroxypropyl methylcellulose, as well as mixtures thereof Other formulations for topical application include shampoos, soaps, shake lotions, and the like, particularly those formulated to leave a residue on the underlying skin, such as the scalp (Arndt et al, in Dermatology In General Medicine 2.2838 (1993)) In general, the concentration of the caspase-14 composition in the topical formulation is in an amount of about 0 5 to 50% by weight of the composition, preferably about 1
to 30%, more preferably about 2-20%, and most preferably about 5-10% The concentration used can be in the upper portion of the range initially, as treatment continues, the concentration can be lowered or the application of the formulation may be less frequent Topical applications are often applied twice daily However, once- daily application of a larger dose or more frequent applications of a smaller dose may be effective The stratum corneum may act as a reservoir and allow gradual penetration of a drug into the viable skin layers over a prolonged period of time In a topical application, a sufficient amount of caspase-14 must penetrate a patient's skin in order to obtain a desired pharmacological effect It is generally understood that the absorption of drug into the skin is a function of the nature of the drug the behaviour of the vehicle, and the skin Three major variables account for differences in the rate of absorption or flux of different topical drugs or the same drug in different vehicles the concentration of drug in the vehicle the partition coefficient of drug between the stratum corneum and the vehicle and the diffusion coefficient of drug in the stratum corneum To be effective for treatment, a drug must cross the stratum corneum which is responsible for the barrier function of the skin In general, a topical formulation which exerts a high in vitro skin penetration is effective in vivo Ostrenga et al (J Pharm Sci , 60 1175-1179 (1971 ) demonstrated that in vivo efficacy of topically applied steroids was proportional to the steroid penetration rate into dermatomed human skin in vitro
A skin penetration enhancer which is dermatologically acceptable and compatible with caspase-14 can be incorporated into the formulation to increase the penetration of caspase-14 from the skin surface into epidemal keratinocytes A skin enhancer which increases the absorption of aminoguanidme into the skin reduces the amount of aminoguanidme needed for an effective treatment and provides for a longer lasting effect of the caspase-14 formulation Skin penetration enhancers are well known in the art For example, dimethyl sulfoxide (U S Pat No 3,711 ,602), oleic acid, 1 ,2- butanediol surfactant (Cooper, J Pharm Sci , 73 1153-1156 (1984)), a combination of ethanol and oleic acid or oleyl alcohol (EP 267,617), 2-ethyl-1 ,3-hexanedιol (WO 87/03490), decyl methyl sulphoxide and Azone RTM (Hadgraft, Eur J Drug Metab Pharmacokmet, 21 165-173 (1996)), alcohols, sulphoxides, fatty acids, esters, Azone RTM , pyrrolidones, urea and polyoles (Kalbitz et al, Pharmazie, 51 619-637 (1996)), terpenes such as 1 ,8-cιneole, menthone, monene and nero dol (Yamane, J Pharmacy & Pharmocology, 47 978-989 (1995)), Azone RTM and Transcutol
(Harrison et al, Pharmaceutical Res 13 542-546 (1996)), and oleic acid, polyethylene glycol and propylene glycol (Singh et al, Pharmazie, 51 741-744 (1996)) are known to improve skin penetration of an active ingredient
Levels of penetration of an caspase-14 composition can be determined by techniques known to those of skill in the art For example, radio-labeling of caspase-14, followed by measurement of the amount of radio-labelled caspase-14 absorbed by the skin enables one of skill in the art to determine levels of the composition absorbed using any of several methods of determining skin penetration of the test compound Publications relating to skin penetration studies include Remfenrath, W G and G S Hawkins The Weanling Yorkshire Pig as an Animal Model for Measuring Percutaneous Penetration In Swine in Biomedical Research (M E Tumbleson, Ed ) Plenum, New York, 1986, and Hawkins, G S Methodology for the Execution of In Vitro Skin Penetration Determinations In Methods for Skin Absorption B W Kemppamen and W G Reifenrath, Eds , CRC Press, Boca Raton, 1990, pp 67-80, and W G Reifenrath, Cosmetics & Toiletries 110 3-9 (1995)
For some applications, it is preferable to administer a long acting form of caspase-14 composition using formulations known in the arts, such as polymers Caspase-14 can be incorporated into a dermal patch (Jungmger, H E , in Acta Pharmaceutica Nordica 4 117 (1992), Thacharodi et al, in Biomateπals 16 145-148 (1995), Niedner R , in Hautarzt 39 761 -766 (1988)) or a bandage according to methods known in the arts to increase the efficiency of delivery of the drug to the areas to be treated Optionally, the topical formulations of this invention can have additional excipients for example, preservatives such as methylparaben, benzyl alcohol, sorbic acid or quaternary ammonium compound, stabilizers such as EDTA, antioxidants such as butylated hydroxytoluene or butylated hydroxanisole, and buffers such as citrate and phosphate
Other therapeutic agents suitable for use herein are any compatible drugs that are effective for the intended purpose, or drugs that are complementary to the caspase-14 formulation As an example, the treatment with an formulation of this invention can be combined with other treatments such as a topical treatment with corticosteroids calcipotπne, coal tar preparations, a systemic treatment with methotrexate, retmoids, cyclospoπn A and photochemotherapy The combined treatment is especially important for treatment of an acute or a severe skin proliferation disease The caspase-14 formulation utilized in a combination therapy may be administered
79
simultaneously, or sequentially with other treatment, such that a combined effect is achieved
Unless stated otherwise in the Examples, all recombinant DNA techniques are performed according to protocols as described in Sambrook et al (1989), Molecular
Cloning A Laboratory Manual Cold Spring Harbor Laboratory Press NY or in
Volumes 1 and 2 of Ausubel et al (1994) Current Protocols in Molecular Biology
Current Protocols
The present invention is further described by reference to the following non-limiting examples whereas a material and method section is enclosed for sake of clarity too
Examples
Materials and methods
Human caspase-14 cDNA cloning
Human skin RNA was prepared from cultured normal human keratinocytes, first strand cDNA was prepared using the Superscript Preamplification System for First strand cDNA synthesis (Gibco BRL) This keratmocyte cDNA was used to obtain a fragment containing full length human procaspase-14 or procaspase-14Λp (procaspase- 4 lacking the putative prodomain consisting of 13 ammo acids) by means of PCR technology [forward PCR primer ATAAGAATGCGGCCGCAAGCAATCCGCGGTCTTTGGAAGAGGAG; forward PCR Δp primer ATAAGAATGCGGCCGCAATGTCAGGTGCCCGCCTGGCCCTA; reverse PCR primer GCTAGCTAGCCTGCAGATACAGCCGTTTCCGGAG; hcaspase-14 matching sequences are indicated in bold These Notl/Nhel digested amphcons were provided with a N-termmal flag tag and a C-termmal myc tag in a modified pCDNA3 vector (Invitrogen, San Diego, CA, USA) to generate the pCDNA-flag-hCASPASE-14-myc and pCDNA-flag-hCASPASE-14Δp-myc vectors
Transient transfection of HEK293T or MCF-7 and detection of apoptotic cells HEK293T is a human embryonal kidney carcinoma stably transfected with the SV40 T- antigen (DuBπdge et al , 1987) These cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, nonessential ammo acids, L- glutamine, and penicillin/streptomycin Human breast carcinoma MCF-7 cells were maintained in RPMI1640 containing 5% fetal calf serum, 5% newborn calf serum, nonessential ammo acids, L-glutamine, and penicillin/streptomycin
5x10 HEK293T or MCF-7 cells were seeded per well (6-well plate) and transiently transfected, 1 μg of total plasmid DNA, by the lipofection method (FuGene, Boehringer). The cells were co-transfected with pEGFP.N1 (a plasmid constitutively expressing green fluorescent protein (GFP)) and pCDNA3flag (control vector), pSVsportmC14 (Van De Craen et al 1998a), pCDNA3-mCASP-14 (Van De Craen et al., 1998a), pCDNA3-fiag-hCASP-14-myc, pcDNA3-flag-hCASP-14ΔP-myc or pCAGGS-mCASP-8 (Van de Craen et al , 1998b) 24h after transfection the GFP- positive population was population was analysed for apoptotic morphology by means of fluorescence microscopy. Immunohistochemistry
Mouse embryos and skin tissues from humans and C57BI/6 mice were fixed in 4% para-formaldehyde, paraffine embedded and sliced (4-6μm). Endogenous peroxidase was blocked with Peroxidase Blocking Reagent (Dako). Both murine and human caspase-14 were stained by a rabbit polyclonal antibody originally raised against recombinant, bacterially expressed murine caspase-14. All antibodies were diluted in phosphate buffered saline (PBS) and the primary antibody was detected by an indirect peroxidase antibody conjugate technique The sections were incubated with a rat anti- rabbit (Dako) for 45 minutes 3- ammo- 9- ethyl carbazole (AEC, Dako) was used as a chromogen for demonstration of the complex. The specificity of the immunohistochemical reactions was checked by omitting the primary antibody or substituting the antι-caspase-14 antibody by an unrelated antibody at the same concentration. Keratinocyte culture HaCaT cells were grown in DMEM supplemented with 10% FCS. Normal human keratinocytes (NHK) were isolated from foreskins of young donors as described (Kitano and Okada, 1983) NHK cells were grown in Keratinocyte Serum Free medium (GIBCO BRL) with a calcium concentration of 0.09 mM and supplemented with 50 μg of bovin pituitary extract per ml and 5 ng of human epidermal growth factor per ml (GIBCO BRL). Third to fifth passage cells were used. Keratinocyte differentiation assays
HaCaT or NHK cells were grown post confluence in the same medium as used for keratinocyte culture. Suspension culture was carried out as described (Watt, 1994). Briefly, after trypsinization, keratinocytes, were suspended in keratinocyte serum-free medium (107 per ml). This liquid suspension was then diluted (1.10) in keratinocyte
serum-free semisolid medium containing the aforementioned supplements and 2% methylcellusose (Aldπch, Bornem, Belgium) and incubated on 0 4% poly(2- hydroxyethylmethylacrylate) (Sigma, St Louis, MO) coated dishes Vitamin D treatment was performed in Keratinocyte Serum Free medium without insulin, thyroid hormone, and hydrocortisone because higher vitamin D anti- proliferative activity was described in the absence of insulin (Chen et al, 1995) Vitamin D was added from a stock solution of 10"4 M per ml in absolute ethanol 1 ,25- dihydroxyvitamm D3 was purchased from Sigma Chemical Co (St Louis MO) The cells were given fresh medium, containing the vitamin D every 24 hours Immunoblot analysis
Transfected cells, differentiated keratinocytes or skin tissue were lysed in a buffer containing 1 % NP-40, 200 mM NaCI, 10mM Tns HCI pH7-7 5, 5 mM EDTA, 10% glycerol, 1 mM PMSF, 0 1 mM aprotmm and 1 mM leupeptm These lysates were immunoblotted with the indicated antibodies Anti-keratin 10 and anti- human caspase- 3 were purchased from Santa-Cruz and Biosource, respectively Antibodies against murine caspases were raised by injecting rabbits with purified, bacterially expressed caspase preparations (Van de Craen et al , 1999) Note that the anti-muπne caspase- 14 antibody cross-reacts with human caspase-14 on western blots as well as on immunohistochemistry staining In vitro transcription/translation pCDNA-plasmids containing mouse or human caspase-14 full length cDNA (pDNA1mCASP-14 and pCDNA3hCASP-14) were used to produce radiolabelled precursor caspase-14 by coupled transcription/translation (TNT kit from Pomega) In vitro caspase-14 cleavage assay 2 microliter of in vitro radiolabelled caspase-14 was incubated with 5 μg of skin or cell lysates in a total volume of 25 μl caspase buffer (50 mM HEPES, pH7 5, 1mM EDTA, 10 mM DTT, 1 mM PMSF, 50 μM leupeptin and 20 μg/ml aprotmm) for 90 minutes at 37 °C Skin and cell lysates were prepared in a buffer containing 1 % NP-40, 200 mM NaCI, 10 mM Tns HCI pH 7 0 to 7 5, 5 mM EDTA 10% glycerol 1 mM PMSF 50 μM leupeptin and 20 μg/ml aprotmm In case of addition of caspase inhibitors, these were used at a final concentration of 10 μM and pre- cubated with the lysates for 30 minutes at 37 °C The resulting cleavage products were analysed on a 15% SDS- PAGE
Results
1) Overexpression of procaspase-14 does not induce cell death or autoprocessing.
In previous experiments we showed that overexpression of murine caspase-14 did not induce cell death (Van de Craen et al 1998a) To examine whether overexpression of human caspase-14 is able to induce cell death, HEK293T or MCF-7 cells were transiently transfected with different vectors containing mouse or human procaspase-14 Since it has previously been shown that caspase-8 is capable of inducing apoptosis in both cell lines (Boldm et al 1996, Muzio et al , 1996), a caspase- 8 expression vector was used as a positive control A vector coding for GFP was co- transfected, which made it possible to visualise the transfected population by fluorescence microscopy and analyse whether the cells had the morphological features of apoptotis In HEK293T cells or MCF-7 cells overexpression of caspase-8 resulted respectively in 89% or 80% cell death 24h after transfection (Fig 1A) However, in neither of both cell lines transient overexpression of human caspase-14 did result in any cell death Removal of a putative 13 ammo acids long prodoma contained in human caspase-14 did neither result in apoptosis
Upon overexpression caspases do autoprocess, thereby generating the p10 and p20 subunits, resulting in fully enzymatically active caspase eventually leading to cell death (Molmeaux et al , 1993, Kamens et al , 1995, Van de Craen et al , 1997 and 1998b) By means of western blot analysis human caspase-14 processing was evaluated Overexpression of caspase-14 nor with or without the putative prodomam in MCF-7 or HEK293T did not result in processing (Fig B) This in contrast to other short prodomam caspases such as caspase-3, -6 and -7 that show autoprocessing resulting in the appearance of proteolytic fragments corresponding to large and small subunits, when overexpressed in HEK293T cells (Fig 1C)
2) Caspase-14 expression is restricted to epithelia of ectodermal origin. previously it was shown that the tissue distribution of caspase-14 mRNA is limited to the adult skin and embryo (Van de Craen et al , 1998a) To further investigate where exactly caspase-14 is expressed, we performed immunohistochemistry on embryo sections, using a polyclonal antι-mouse-caspase-14 antibody As a negative control the stainmgs were performed with the anti-rabbit-HRP antibody only
Immunostaining of 15 5 dpc embryo sections revealed that caspase-14 is expressed in the differentiated layers of the epidermis (Fig 2A), in the pigmented layer of the retina and in the epithelial cells of the choroid plexus (Fig 2B and C) Caspase- 14 is not expressed in the embryonic skin peπderm or in the basal keratinocyte layers (stratum basale), these layers represent undifferentiated keratinocytes and contain neither the typical differentiation markers of adult skin (Byrne et al , 1994) Moreover, caspase-14 is expressed in the fully developed hair bulb that also consists of differentiated keratinocytes (Hardy 1992) whereas in a premature hair bulb consisting of only cells of the stratum basale there is no caspase-14 expression (Fig 2A)
In addition, the epithelial cells of the choroid plexus stained more strongly in 15 5 dpc embryos than in the 13 5 dpc embryo's In the epithelial cells of the choroid plexus and the retinal pigment layer there is only cytoplasmic expression, while in skin also nuclear expression occurs 3) Caspase-14 is gradually expressed in the differentiating skin
Immunohistochemistry on human skin sections confirmed that the caspase-14 protein is only expressed in the differentiated layers of the epidermis but not in the basal layer (Fig 3). The expression increases gradually in the skin from the stratum spmosum towards the stratum granulosum and the stratum corneum During keratinocyte differentiation the caspase-14 expression also becomes more pronounced in the nucleus especially in the stratum granulosum In a later stage the nucleus gets expulsed, thereby reaching the final stage of differentiation resulting in the formation of the cornified layers The mature hairshaft and the sebaceous gland consist of differentiated keratinocytes (Hardy, 1992), and also here caspase-14 is expressed In the sweat glands, which are of dermal origin, the staining was negative 4) The expression of caspase-14 is drastically reduced in the skin plaques of psoriatic patients.
Psoriasis is a common human disease with distinctive histological hallmarks including epidermal keratinocyte hyperproliferation, abnormal keratinocyte differentiation, parakeratosis and immune cell infiltration Until now it is not clear if psoriasis is caused by a defect in the keratinocyte or the recruited immune cells To evaluate a potential role for caspase-14 in skin pathologies, we analysed samples from psonatic skin plaques by immunohistochemistry with antι-caspase-14 antibodies Plaques from 6 independent psonatic were analysed and compared to the same
number of non-involved patients As is clear from Fig 3 (showing one representative patient from psonatic and non-involved skin) the psonatic plaques show a marked decrease in the expression of caspase-14 In the parakeratotic lesions and in the abnormal, multi-layered stratum basale caspase-14 expression was seemingly absent in case of psonatic skin Non-involved skin stained in a pattern as discussed above These data show an involvement of caspase-14 in abnormal skin differentiation pathologies Strategies to upregulate caspase-14 expression may prove to have an important therapeutic contnbution to diseases involving parakeratosis such as psoriasis 5) Caspase-14 is processed in normal mouse epidermis.
As shown in Fig 1 we were unable to generate processed caspase-14 upon overexpression in HEK293T or MCF-7 cells To analyse if caspase-14 is present in an activated state in developing skin, we made a protein extract of mouse skin and used these lysates for immunoblotting with different rabbit polyclonal anti-caspase antisera In the case of caspase-14 we could clearly detect bands corresponding both to the proenzyme and to the processed p20 fragment (Fig 4) The two bands that can be observed at the size of approximately 20 and 18 5 kDa probably represent the large subunit with and without prodomam, respectively The specificity of these bands for caspase-14 was confirmed in a competition experiment in which the western blot was developed with antι-caspase-14 in the presence of recombinant bacterially expressed caspase-14 Under these conditions any of the antι-caspase-14 stained fragments could be detected, in contrast to incubation with antι-caspase- 4 in the presence of recombinant caspase-3 The typical apoptosis-related caspases such as caspase-3, -6 and -7 were only present as unprocessed proenzymes Although, an involvement of active caspase-3 has been claimed in skin differentiation (Weil et al , 1999) Since it is well documented that IL1 is produced in the skin (Kumar et al , 1992, Boehm et al , 1995, Debets et al , 1995), we also analysed the activation state of caspase-1 and - 11 It has been shown in physiological systems that these two caspases are involved in the processing and secretion of IL1-α and -β (Kuida et al , 1995, Li et al , 1995, Li et al , 1997, Wang et al , 1998) As expected we could detect prototype bands correlating to processed forms of caspase-1 and -1 1
6) The expression of caspase-14 in human keratinocytes is mducible in vitro.
2b
Since caspase-14 is not present in the stratum basale but is expressed in the differentiated layers of the epidermis, we wondered whether the protein expression of caspase-14 in keratinocytes could be induced in vitro by conditions of differentiation In a western blot experiment it was shown that cell lysates of undifferentiated HaCaT cells or normal human keratinocytes do not contain caspase-14 (Fig 5A), which was expected since these undifferentiated cells represent the stratum basale cells of the epidermis where no caspase-14 is expressed
Primary human keratinocytes grown in suspension or post confluence express several differentiation markers such as keratin 1 and 10, involucπn and transglutaminase (Poumay and Pittelkow, 1995) We could show that in cells grown under these differentiating conditions caspase-14 was expressed together with keratin 10 (Fig 5A and B) In contrast, caspase-3 expression was hardly affected when cells were grown post confluence These differentiation conditions did not lead to the processing of caspase-3 or -14 As a control for caspase-3 processing lysates were loaded derived from U937 cells treated with TNF and cycloheximide
Treatment of keratinocytes with 1 ,25-dιhydroxyvιtamιn D3 also induces these cells to differentiate (Hosomi et al , 1983 Bikle and Pillai, 1993 Chen et al , 1995) HaCat keratinocytes were treated with different concentrations of vitamin D and cells were lysed 72h after treatment We were able to show that vitamin D is capable of inducing the expression of procaspase-14 in a dose-dependent way, reaching a maximal level at 10 7 to 10 6 M (Fig 6A) This concentration range of vitamin D has also been described as the optimal concentrations for vitamin D-mduced anti- proliferative effects on keratinocytes (Simpson et al , 1980, Segaert et al , 1997) The non-treated cells also express low levels of procaspase-14 due to post confluent growth of the cells at this time-point. Moreover, keratin 10 was expressed in these cultures, indicating that differentiation was already occurring Vitamin D treatment does not enhance the expression of keratin 10, however apparently its expression could no longer be detected when vitamin D was added at a concentration of 106 M It is possible that at this concentration keratinocyte differentiation reaches its final stage, eventually leading to the formation of keratin complexes that are not solubilised in classical lysis buffers (Eichner et al , 1989 and 1990) To analyse the vitamin D- mduced caspase-14 expression in time, we performed a kinetics experiment in which HaCat cells treated with a fixed concentration of 1 ,25-dιhydroxyvιtamιn D3 (107M) and lysed after 24, 48, 72 and 96 hours (Fig 6B) Caspase-14 was increasingly expressed
from 48 hours on, to 96 hours treatment Background expression of caspase-14 increased in time due to the post confluent differentiation state of the cells, as shown by keratin 10 expression In neither condition we were able to observe fragments of caspase-14 pointing to processing of caspase-14, as was observed in mouse skin lysates (Fig 4) Again, the caspase-3 expression or processing level was not affected by treatment with vitamin D, or by post confluent growth This in contrast to the proposed role of activated caspase-3 in keratinocyte differentiation (Weil er al 1999) 7) Caspase-14 is activated during epidermal differentiation
To determine the kinetics of caspase-14 activation during epidermal differentiation we monitored the appearance of its cleavage products during the formation of epidermal equivalents (EE i e in vitro reconstituted epidermis purchased from Mattek Corp Ashland M A ) EE consists of several layers of differentiating KC and form a stratum corneum comparable to that of normal human epidermis in vivo and can therefore be considered an in vitro model for terminal differentiation of KC For the analysis of the time course of caspase-14 processing, EE were either left submerged in culture medium or lifted to the air-liquid interface after onset of stratification Samples obtained at different timepoints were stored frozen on dry ice until further analysis
Wesiem bioi analysis for casμase-14 was performed with lysates of EE Specificity of the antibody was controlled by pre-mcubation with recombinant caspase- 14 Kinetics of caspase-14 cleavage was studied by analysing EE at 2 4 and 7 days after lifting at the air liquid interface In parallel EE maintained submerged in culture medium were tested Morphology of submerged EE and EE lifter to the interface was analysed by hematoxylin eosm staining of paraffin sections For Western blot analysis all samples were lysed in SDS-lysis buffer (62 5 mM
Tπs/HCI, pH 6 8, 6M urea, 2% SDS, 0 00125% bromophenolblue, 5% β- mercaptoethanol) After ultrasonification and removal of insoluble cell debris, 40μg of protein were electrophoresed through a 8% to 18% gradient polyacrylamide gel and blotted onto a nitrocellulose membrane (Bio-Rad, Hercules, CA) Blots were blocked for 3 h in blocking buffer (PBS with 7 5% nonfat dry milk, 2% BSA, 0 1 %Tween) and incubated with caspase-14 specific antiserum diluted 1 1000 in blocking buffer overnight at 4 C Subsequently, membranes were washed in PBS with 5% nonfat dry milk, 0 1 % Tween, incubated with peroxidase-conjugated goat anti-rabbit IgG Fc antibody (Pierce 1 10000 in blocking buffer) for 1 h at room temperature washed in
PBS and developed using the ECL chemiluminescent detection system (Amersham) As control the antι-caspase-14 antiserum was premcubated with 10 μg/ml recombinant mouse caspase-14 for 1 hour at room temperature
Thus, in this system, the exposure of the culture to air is a strong stimulus for the formation of a regular epidermis (Asselineau et al , 1985) Therefore we compared EE cultured at the air-liquid interface with EE left submerged in the medium Under submerged conditions, EE failed to differentiate and did not form a regular stratified epidermis After 7 days the uppermost KC layers still contained nuclei Although high amounts of the caspase -14 proenzyme (28kD) were detectable via Western blot at all time points, only minute amounts of caspase-14 cleavage products (1 1 and 17kD) could be detected after 7 days By contrast in EE which were lifted at the air liquid interface, KC differentiation proceeded to the formation of a well structured stratum corneum, devoid of nuclei In lysates of these EE, subunit bands of caspase-14 demonstrating its activation were present already two days after lifting EE to the air- liquid interface and strong processing was observed on day 7
8) Regulation of caspase-14 expression by vitamin D treatment of psoriatic skin Skin samples were derived from psonatic patients Psonatic plaques were treated with calcipotπol-Daivonex The treatment with calcipotπol was two times per day and was applied in a salve Non-involved skin from the same patients served as a control Biopsies of the psonatic plaques were taken before and after treatment Skin samples were fixed, paraffin embedded and sliced Caspase-14 protein expression was detected by means of immunohistochemistry using a polyclonal antι-caspase-14 antibody The vitamin D treatment clearly results in an increased expression of caspase-14 in all suprabasal layers, including the parakeratotic plaques Both nuclear and cytoplasmic staining was increased by the treatment Also the thickening of the psonatic skin is significantly reduced by treatment with vitamin D Seven patients were treated with vitamin D and analysed for caspase-14 expression All patients gave similar results (see table 1 )
9) Caspase-14 expression is reduced in papillomas and carcinomas of the choroid plexus
We analyzed caspase-14 expression by means of immunohistochemistry in human papillomas and carcinomas of the choroid plexus and compared this expression to normal levels of expression in the epithelium of the choroid plexus Caspase-14 expression could be demonstrated in the epithelial cells of normal choroid plexus
whereas caspase-14 expression in both papilloma and carcinoma of the choroid plexus was strongly reduced (see Figure 7) These tumors share with the normal choroid plexus the property of cerebrospmal fluid (CSF) production Overproduction of CSF by these tumours is a well-recognized phenomenon, eventually leading to 5 hydrocephalus Since a reduced caspase-14 expression level correlates with a dysfunctional choroid plexus epithelium, increasing caspase-14 expression by use of caspase-14 expression modulators or by gene therapy restores normal functioning of the choroid plexus
10) Regulation of caspase-14 expression in keratinocyte cultures by vitamme D, l o retinoic acid, lithium salts and glucocorticoids
Induction of caspase-14 protein expression was further analyzed upon treatment of HaCaT cells with vitamin D3 retmoic acids LiCI, cytokmes or glucocorticoids Before treatment the cells were grown subconfluent or induced to differentiate and express procaspase-14 by means of post-confluent growth The cells that were grown
15 subconfluent do not express caspase-14 However, the expression of procaspase-14 could be induced by treatment of the cells with vitamin D3, LiCI or hydrocortisone In cells grown post-confluent the caspase-14 expression level augmented upon treatment with vitamin D3, LiCI or hydrocortisone and was lower after treatment with retmoic acids Both 9-c/s retmoic acid and a\\-trans retmoic acid were used All-frans 0 ret oic acid at concentrations less then 10 6M and 9-c/s retmoic acid have been described as antagonists for vitamin D dependent antiproliferative activity while at pharmacologic concentrations 10 6M) all-frans retmoic acid can potentiate this effect In the sub- or post-confluent grown cells the vitamin D3 inducing effect on caspase-14 expression could be inhibited by addition of retmoic acids At concentrations lower 5 than 10"6M a\\-trans retmoic acid, there was less inhibition on the vitamin D dependent induction of caspase-14 expression Cytokmes (TNF, IL-1 beta, IFN-gamma) did not influence caspase-14 expression, although the inducing effect of LiCI was inhibited in combination with TNF (see Fig 8)
11) Modulation of caspase-14 via nucleic acids encoding for caspase-14 affects 30 skin differentiation
The effect on skin differentiation of overexpression or downregulation of caspase-14 is monitored in vitro Therefore retroviral expression vectors are developed containing wild-type caspase-14 (over-expression), a catalytically inactive caspase-14 mutant that could act as a dominant-negative form of caspase-14 (downregulation) or an antisense
caspase-14 sequence (downregulation) The catalytically inactive mutant is obtained by modifying the catalytic important residues such as Hιs89 or Cys132 (referring to the human caspase-14 sequence as previously referred to) to Ala Examples of retroviral vectors used for transfection of keratinocytes are EBV-based vectors such as the LZRS retroviral vector (Seitz et al , 1998) or pBabe puro (Lowell et al , 2000) These vectors are then used to transfect primary keratinocyte cultures with an > 99 % transfection efficiency The transfected keratinocytes are then used in an in vitro epidermal differentiation assay and the effect of upregulation or downregulation of caspase-14 on the outcome of the epidermal differentiation is monitored by means of histological analysis and western blotting The western blotting indicates to what level caspase-14 is upregulated/down-regulated and processed when compared to control cultures
12) Skin lysates contain a caspase-14 processing activity In vitro translated and radioactive 35S-methιonιne labelled murine or human procaspase-14 was incubated with lysates of undifferentiated or differentiated keratinocytes (HaCaT or NHK cells), or lysates of mouse skin (C57BL/6 mice) for 90 minutes at 37°C and analysed by means of SDS-PAGE and autoradiography The differentiated keratinocytes were obtained by growing these cells postconfluence, this condition was shown to upregulate caspase-14 expression but not processing Both mouse and human caspase-14 were processed to its catalytic subunits p20 and p10 by an enzymatic activity present in the mouse C57BL/6 skin lysate This activity was neither detectable in lysates of undifferentiated nor in vitro differentiated (postconfluence = pc) keratinocytes These data correlate with our observations that in skin caspase-14 is present in its processed form and that postconfluence grown keratinocytes only show procaspase-14 expression To test if a known caspase-activity could be responsible for the caspase-14 processing activity present in skin lysates, we incubated these lysates with different peptide inhibitors before co-incubation with the labelled procaspase-14 for 30 minutes at 37 °C None of the used inhibitors affected the procaspase-14 processing activity present in skin lysates We used the well-known caspase inhibitors zVAD, BocD, DEVD and YVAD and the cathepsm B inhibitor zFA
References
Asselineau D, Bemhard B, Bailly C, Darmon M, Epidermal morphogenesis and induction of the 67 kD keratin polypeptide by culture of human keratinocytes at the liquid-air interface Exp Cell Res 1985 Aug, 159(2) 536-9
Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD Flow cytometnc identification of pro ferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis J Exp Med 1993 Oct 1 ,178(4) 1271-81 Bikle DD, Pillai S Vitamin D calcium and epidermal differentiation Endocr Rev 1993 Feb,14(1 ) 3-19
Boehm KD, Yun JK Strohl KP, Elmets CA Messenger RNAs for the multifunctional cytokmes ιnterleukιn-1 alpha ιnterleukιn-1 beta and tumor necrosis factor-alpha are present in adnexal tissues and in dermis of normal human skin Exp Dermatol 1995 Dec,4(6) 335-41
Boldm MP, Goncharov TM, Goltsev YV, Wallach D Involvement of MACH, a novel MORT1/FADD-ιnteractιng protease, in Fas/APO-1- and TNF receptor-induced cell death Cell 1996 Jun 14,85(6) 803-15 Byrne C, Tamsky M, Fuchs E Programming gene expression in developing epidermis Development 1994 Sep, 120(9) 2369-83
Chen TC, Persons K, Liu WW, Chen ML Holick MF The antiproliferative and differentiative activities of 1 ,25 dihydroxyvitamin D3 are potentiated by epidermal growth factor and attenuated by insulin in cultured human keratinocytes J Invest Dermatol 1995 104 113-117 Debets R Hegmans JP Troost RJ Benner R Prens EP Enhanced production of biologically active ιnterleukιn-1 alpha and ιnterleukιn-1 beta by psonatic epidermal cells ex vivo evidence of increased cytosolic ιnterleukιn-1 beta levels and facilitated ιnterleukιn-1 release Eur J Immunol 1995 Jun,25(6) 1624-30 DuBndge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system Mol Cell Biol 1987 Jan,7(1) 379-87
Eichner R, Sun TT, Aebi U The role of keratin subfamilies and keratin pairs in the formation of human epidermal intermediate filaments J Cell Biol 1986 May, 102(5) 1767-77
Eichner R, Kahn M Differential extraction of keratin subunits and filaments from normal human epidermis J Cell Biol 1990 Apr, 110(4) 1149-68
Fogh K, Kragballe K Vitamin D3 analogues Clin Dermatol 1997 Sep-Oct, 15(5) 705-
13 Fu GK, Portale AA, Miller WL Complete structure of the human gene for the vitamin D lalpha-hydroxylase, P450c1alpha DNA Cell Biol 1997 Dec,16(12) 1499-507
Gandanllas A, Goldsmith LA, Gschmeissner S, Leigh IM, Watt FM Evidence that apoptosis and terminal differentiation of epidermal keratinocytes are distinct processes Exp Dermatol 1999 Feb,8(1 ) 71-9 Gandanllas A, Watt FM c-Myc promotes differentiation of human epidermal stem cells Genes Dev 1997 Nov 1 ,11 (21 ) 2869-82
Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA CD95-ιnduced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance Immunity
1996 Jul, 5(1 ) 7-16 Haake AR, Polakowska RR Cell death by apoptosis in epidermal biology J Invest
Dermatol 1993 Aug, 101 (2) 107-12
Hardy MH The secret life of the hair follicle Trends Genet 1992 Feb,8(2) 55-61
Hollick JB, Dorweiler JE, Chandler VL Paramutation and related allelic interactions
Trends Genet 1997 Aug, 13(8) 302-8 Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T Regulation of terminal differentiation of cultured mouse epidermal cells by 1 ,25 dihydroxyvitamin D3 Endocrinology
1983, 113 1950-1957
Humke EW, Ni J, Dixit VM ERICE, a novel FLICE-activatable caspase Biol Chem
1998 Jun 19,273(25) 15702-7 Ishizaki Y, Jacobson MD Raff MC A role for caspases in lens fiber differentiation J
Cell Biol 1998 Jan 12,140(1 ) 153-8
Kamens J, Paskmd M, Hugunm M, Talanian RV, Allen H, Banach D, Bump N, Hackett
M, Johnston CG, Li P, et al Identification and characterization of ICH-2, a novel member of the ιnterleukιn-1 beta-converting enzyme family of cysteme proteases J Biol Chem 1995 Jun 23,270(25) 15250-6
Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, Flavell RA Altered cytokme export and apoptosis in mice deficient in ιnterieukιn-1 beta converting enzyme Science 1995 Mar 31 ,267(5206) 2000-3
Kumar S, Millis AJ, Bag oni C Expression of interleukm 1-ιnducιble genes and production of interleukm 1 by aging human fibroblasts Proc Natl Acad Sci U S A 1992
May 15,89(10) 4683-7
Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskmd M Rodman L, Salfeld J, et al Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock Cell 1995 Feb
10,80(3) 401-1 1
Lu QL, Poulsom R, Wong L, Hanby AM Bcl-2 expression in adult and embryonic non- haematopoietic tissues J Pathol 1993 Apr, 169(4) 431-7 McCall CA, Cohen JJ Programmed cell death in terminally differentiating keratinocytes role of endogenous endonuclease J Invest Dermatol 1991
Jul,97(1) 111-4
McCall K, Steller H Requirement for DCP-1 caspase during Drosophila oogenesis
Science 1998 Jan 9,279(5348) 230-4 Molmeaux SM, Casano FJ, Rolando AM, Peterson EP, Limjuco G, Chin J, Griffin PR,
Calaycay JR, Ding GJ, Yamin TT, et al Interleukm 1 beta (IL-1 beta) processing in murine macrophages requires a structurally conserved homologue of human IL-1 beta converting enzyme Proc Natl Acad Sci U S A 1993 Mar 1 ,90(5) 1809-13
Muzio M, Chmnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM FLICE, a novel FADD-homologous ICE/CED-3-lιke protease, is recruited to the CD95
(Fas/APO-1) death-inducing signaling complex Cell 1996 Jun 14,85(6) 817-27
Polakowska RR Piacentmi M, Bartlett R Goldsmith LA Haake AR Apoptosis in human skin development morphogenesis, peπderm, and stem cells Dev Dyn 1994 Mar, 199(3) 176-88
Poumay Y, Pittelkow MR Cell density and culture factors regulate keratinocyte commitment to differentiation and expression of suprabasal K1/K10 keratins J Invest
Dermatol 1995 Feb, 104(2) 271-6
Ragaz A, Ackerman AB Evolution, maturation, and regression of lesions of psoriasis New observations and correlation of clinical and histologic findings Am J
Dermatopathol 1979 Fall, 1 (3) 199-214
Rice RH, Mehrpouyan M, O'Callahan W, Parenteau NL, Rubin AL Keratinocyte transglutammase differentiation marker and member of an extended family Epithelial
Cell Biol 1992 Jul, 1 (3) 128-37
Segaert S, Garmyn M, Degreef H, Bouillon R Retmoic acid modulates the anti- pro ferative effect of 1 25-dιhydroxyvιtamιn D3 in cultured human epidermal keratinocytes J Invest Dermatol 1997 Jul, 109(1 ) 46-54
Simpson RU, DeLuca HF Characterization of a receptor-like protein for 1 ,25- dihydroxyvitamin D3 in rat skin Proc Natl Acad Sci U S A 1980 Oct,77(10) 5822-6 Streilem JW Immunoregulatory mechanisms of the eye Prog Retm Eye Res 1999 May, 18(3) 357-70
Takahashi T, Ogo M, Hibmo T Partial purification and characterization of two distinct types of caspases from human epidermis J Invest Dermatol 1998 Sep, 111 (3) 367-72 Van de Craen M, Declercq W, Van den brande I, Fiers W & Vandenabeele P The proteolytic procaspase activation network an in vitro analysis Cell Death Differ 1999 In press
Van de Craen M, Van Loo G, Declercq W, Schotte P, Van den brande I, Mandruzzato S, van der Bruggen P, Fiers W, Vandenabeele P Molecular cloning and identification of murine caspase-8 J Mol Biol 1998b Dec 1 1 284(4) 1017-26
Van de Craen M, Van Loo G, Pype S, Van Cnekinge W, Van den brande I, Molemans F, Fiers W, Declercq W, Vandenabeele P Identification of a new caspase homologue caspase-14 Cell Death Differ 1998a Oct,5(10) 838-46 Van de Craen M, Vandenabeele P, Declercq W, Van den Brande I, Van Loo G, Molemans F, Schotte P, Van Cnekinge W, Beyaert R, Fiers W Characterization of seven murine caspase family members FEBS Lett 1997 Feb 10,403(1 ) 61-9 van de Kerkhof PC Biological activity of vitamin D analogues in the skin, with special reference to antipsonatic mechanisms Br J Dermatol 1995 May, 132(5) 675-82 Wang S, Miura M, Jung YK, Zhu H, Li E, Yuan J Murine caspase-11 , an ICE- interacting protease, is essential for the activation of ICE Cell 1998 Feb 20,92(4) 501- 9
Weil M, Raff MC, Braga VM Caspase activation in the terminal differentiation of human epidermal keratinocytes Curr Biol 1999 Apr 8 9(7) 361-4
Claims
Claims
Use of modulators of caspase-14 bioactivity, nucleic acids encoding caspase- 14 and/or caspase-14 protein for the manufacture of a medicament that modulates keratinocyte differentiation and/or the blood-eye barrier and/or the blood-brain barrier Use according to claim 1 wherein said modulators are chosen from the group comprising modulators of caspase-14 expression, modulators of caspase-14 activation and/or bioactivity, and/or fragments of said modulators that modulate keratinocyte differentiation and/or the blood-eye barrier and/or the blood-brain barrier Use according to claim 2, wherein said modulators of caspase-14 activation and/or bioactivity are modulators that bind to caspase-14 protein Use according to claim 3, wherein said modulators that bind to caspase-14 protein are antibodies and/or fragments thereof that modulate keratinocyte differentiation and/or the blood-eye barrier and/or the blood-brain barrier Use according to claim 2, wherein said modulators of caspase-14 expression are chosen from the group comprising anti-sense nucleic acids that hybridize with nucleic acids encoding caspase-14 or fragments thereof, ribozymes, vitamme D or homologues thereof, retmoic acid or homologues thereof, transformation growth factor-beta or homologues thereof, glucocorticoids and homologues thereof, lithium salts and calcium salts Use according to claim 5 wherein said vitamme D is vitamme D3, wherein said glucocorticoid is hydrocortisone and wherein said lithium salt is lithiumchloπde Use of modulators of caspase-14 bioactivity, nucleic acids encoding caspase-
14 and/or caspase-14 protein for the manufacture of a medicament for treating disorders of keratinocyte differentiation, disturbances in the blood-eye barrier and brain disorders Use of nucleic acids hybridising with nucleic acids encoding for caspase-14 or fragments thereof, or, molecules specifically binding to caspase-14 protein and/or fragments thereof for the manufacture of a diagnostic assay for disorders of keratinocyte differentiation, disturbances in the blood-eye barrier and/or disturbances in the blood-brain barrier A pharmaceutical composition comprising modulators of caspase-14 bioactivity,
nucleic acids encoding caspase-14 and/or caspase-14 protein. 10. A pharmaceutical composition according to claim 9 wherein said modulators are chosen from the group comprising modulators that bind to caspase-14 protein, anti-sense nucleic acids that hybridize with nucleic acids encoding caspase-14 or fragments thereof, ribozymes, vitamine D or homologues thereof, retinoic acid or homologues thereof, transforming growth factor-beta or homologues thereof, glucocorticoids and homologues thereof, lithium salts and calcium salts.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00977538A EP1227834A2 (en) | 1999-11-10 | 2000-11-10 | Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99203752 | 1999-11-10 | ||
EP99203752 | 1999-11-10 | ||
EP00202776 | 2000-08-04 | ||
EP00202776 | 2000-08-04 | ||
PCT/EP2000/011251 WO2001034183A2 (en) | 1999-11-10 | 2000-11-10 | Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders |
EP00977538A EP1227834A2 (en) | 1999-11-10 | 2000-11-10 | Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1227834A2 true EP1227834A2 (en) | 2002-08-07 |
Family
ID=26072576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00977538A Withdrawn EP1227834A2 (en) | 1999-11-10 | 2000-11-10 | Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1227834A2 (en) |
AU (1) | AU1521501A (en) |
CA (1) | CA2390510A1 (en) |
WO (1) | WO2001034183A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1384468A1 (en) * | 2002-07-25 | 2004-01-28 | Cognis France S.A. | Method for protecting and for modulating tight junctions |
EP1384469A1 (en) * | 2002-07-25 | 2004-01-28 | Cognis France S.A. | Method for protecting and for modulating tight junctions |
CA2661668A1 (en) * | 2006-09-01 | 2008-03-06 | Vib Vzw | Sunscreen compositions |
JP5562015B2 (en) * | 2009-12-04 | 2014-07-30 | 株式会社 資生堂 | Screening method for skin barrier function recovery promoting substance |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5037816A (en) * | 1984-11-02 | 1991-08-06 | The General Hospital Corporation | Method of treating psoriasis |
GB8719988D0 (en) * | 1987-08-25 | 1987-09-30 | Efamol Ltd | Chemical compounds |
KR920002163B1 (en) * | 1988-08-05 | 1992-03-19 | 온코겐, 어 리미티드 파트너쉽 | Psoriasis treatment with tgf-beta |
WO1992013551A1 (en) * | 1991-02-04 | 1992-08-20 | Oncogene Science, Inc. | Inhibition of multidrug transport by transforming growth factor beta and uses thereof |
FR2726187A1 (en) * | 1994-10-26 | 1996-05-03 | Jean Noel Thorel | Topical compsns. contg. calcium chloride |
US5716627A (en) * | 1996-04-25 | 1998-02-10 | Elizabeth Arden Co., Division Of Conopco, Inc. | Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester |
US6432628B1 (en) * | 1997-08-26 | 2002-08-13 | Thomas Jefferson University | Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use |
WO1999023106A1 (en) * | 1997-10-30 | 1999-05-14 | Human Genome Sciences, Inc. | Caspase-14 polypeptides |
EP1100933A1 (en) * | 1998-07-17 | 2001-05-23 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | New caspase homologue |
-
2000
- 2000-11-10 WO PCT/EP2000/011251 patent/WO2001034183A2/en active Search and Examination
- 2000-11-10 CA CA002390510A patent/CA2390510A1/en not_active Abandoned
- 2000-11-10 EP EP00977538A patent/EP1227834A2/en not_active Withdrawn
- 2000-11-10 AU AU15215/01A patent/AU1521501A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0134183A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2390510A1 (en) | 2001-05-17 |
WO2001034183A2 (en) | 2001-05-17 |
WO2001034183A3 (en) | 2001-11-08 |
AU1521501A (en) | 2001-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69736129T2 (en) | Methods and compositions for the treatment of neoplastic diseases | |
JP4574012B2 (en) | Functional antagonist of hedgehog activity | |
JP2008530003A (en) | Use of a myostatin (GDF-8) antagonist for improving wound healing and for preventing fibrosis | |
AU2010217213B2 (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
TWI486168B (en) | Method of treating endothelial dysfunction | |
CZ333595A3 (en) | Recombinant stratum corneum chymotryptic enzyme (scce) | |
US20090318534A1 (en) | Methods and compositions for the treatment of skin diseases and disorders | |
CN110831668A (en) | Plasminogen treatment of conditions associated with PAI-1 overexpression | |
Tripathi et al. | Tissue plasminogen activator in human aqueous humor and its possible therapeutic significance | |
TWI353849B (en) | Methods and compositions for the promotion of hair | |
US11382890B2 (en) | Prevention of rosacea inflammation | |
JP2015536344A (en) | Compositions and methods for the treatment of ectodermal dysplasia | |
JP2007509151A (en) | Methods and compositions for treating 5α-reductase type 1 and type 2 dependent symptoms | |
US9351914B2 (en) | Methods for modulating hair growth using truncated laminin-511 | |
WO2001034183A2 (en) | Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders | |
US20220064243A1 (en) | Agent for treatment of dermatological disorders | |
CA3112558A1 (en) | Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor | |
CN102477410B (en) | The embryonal of the adipose-derived stem cells containing bacillus bifidus extract promote with and skin cell proliferation compositions | |
CN112142856B (en) | Specific degradation NDRG2 targeting peptide for improving cerebral stroke excitotoxic injury and application thereof | |
AU2003200309B2 (en) | Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases | |
CN117942398A (en) | Application of SEMA3C-NRP1/NRP 2-GAS 6/AXL in preparation of medicine for treating onychomycosis | |
KR20220130144A (en) | Cosmetic formulations for topical administration comprising novel peptides that improve skin appearance and regeneration | |
JP2019522675A (en) | Methods of treating injury associated with excitatory neurotoxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020510 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20021023 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050802 |